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Cervical cancer incidence has substantially declined since cervical screening was implemented 
five decades ago. The long-term hope of eliminating cervical cancer is promising with the 
development of effective Human papillomavirus (HPV) vaccines. Optimising effectiveness 
and promoting high and equal uptake of preventive approaches are essential for achieving this 
goal. This thesis aimed to use register data in Sweden to perform in-depth evaluation of the 
effectiveness of cervical screening and investigate the factors associated with HPV vaccine 
uptake. The work focused in detail upon the uncertain preventive effect against cervical 
adenocarcinoma in relation to the finding of glandular abnormalities in screening, the 
effectiveness of screening for the conspicuous incidence of cervical cancer at older ages, as 
well as social disparity of HPV vaccine uptake in different modes of vaccination delivery. 
Effectiveness of cervical screening in preventing invasive cervical cancer has been reported 
under a case-control audit framework in Sweden, based on cervical cancer cases diagnosed in 
1999-2001. Yet, assessing long-term screening history and controlling for confounding factors 
were hampered by unavailable data, and statistical power was limited to stratify the evaluation 
by histopathological type. We therefore performed an updated case-control audit based on 
cervical cancer cases diagnosed in 2002-2011 (Study III), to examine the risk of invasive 
cervical cancer in relation to screening history in the past two screening rounds, adjusted for 
education and stratified by the two main histopathological types. We found that non-routine 
participation to cervical screening was associated with increased risk of invasive cervical 
cancer. Having an abnormality in previous two screening rounds was associated with elevated 
risk, particularly if not being screened in the subsequent screening round after an abnormality. 
The lower effectiveness of cervical screening in preventing adenocarcinoma compared to 
squamous cell carcinoma resulted from both lower assurance from normal screening results, 
and higher risk following abnormalities. These findings reinforce the evidence of the cancer-
preventive effect of cervical screening and emphasise the importance of routine participation 
in screening. We also identify relative weaknesses of the screening programme that would 
guide future research to address improvement.  
Atypical glandular cells (AGC) found in cervical screening is a cytological abnormality of the 
same type of cells giving rise to cervical adenocarcinoma. However, the long-term risk of 
cervical cancer following AGC has not been comprehensively investigated due to its rarity. We 
used the Swedish National Cervical Screening Registry (NKCx) to identify all AGC diagnosed 
in cervical screening from 1980-2011, examined the risk of cervical cancer by 
histopathological type for up to 15 years, and compared the subsequent histological assessment 
and risk of cancer to that after high-grade squamous intraepithelial neoplasia (HSIL) (Study I). 
We found that AGC was associated with a moderate-high proportion of prevalent cancer, and 
a high long-term risk of incident cervical cancer, especially adenocarcinoma. Only 54% of 
AGC were followed by histology within six months, and among those being followed with 
histology, the cancer incidence after AGC was still statistically significantly higher than that 
after HSIL. Our findings confirm the considerable risk associated with AGC and revealed 
suboptimal management following this specific abnormality. We highlight one of the deeper 
causes of unsatisfactory preventive effects of screening against cervical adenocarcinoma, and 
the necessity of improving management practice for AGC. 
Cervical cancer is generally associated with middle-aged women, but the first Swedish case-
control audit revealed that cervical cancer in women over 60 years of age accounted for more 
than one-third of annual cervical cancer cases. Data from other Nordic countries have also 
exhibited similar to higher incidence of cervical cancer among older-aged women compared to 
middle-aged women, leading to uncertainty on the underlying reason of biological or screening 
effect and the effectiveness of cervical screening after age 60. Therefore, we used NKCx and 
the Swedish Cancer Registry to investigate the risk of cervical cancer from age 61-80 years by 
screening history at ages 51-60 years, and evaluated the effectiveness of cervical screening at 
ages 61-65 stratified by screening history (Study II). We found that screening at ages 61-65 
was associated with substantial risk reduction up to age 80 in women unscreened or having 
abnormalities in their 50s. Yet in women screened with normal results in their 50s, the 
subsequent risk of cervical cancer was remarkably lower than that in women unscreened or 
having abnormalities in the past, and in these women screening after age 60 was not associated 
with any statistically significant risk reduction. Our results should inform the current debate 
regarding when and how to discontinue cervical screening in older-aged women. 
HPV vaccines have been available worldwide since 2006-2007. Their efficacy and 
effectiveness in preventing cervical precursor lesions have been shown repeatedly. Pursuing 
high and equal coverage of HPV vaccination is the common goal to reduce inequality of 
cervical cancer development in the future. Various modes of delivery of HPV vaccination were 
implemented worldwide and in Sweden. We used Swedish vaccination registers and social-
demographic registers to examine girls’ HPV vaccine uptake in relation to parental country of 
birth, education and family income, by three delivery modes of HPV vaccination (Study IV). 
We found that free-of-charge school-based delivery achieved the highest uptake of HPV 
vaccination with the lowest social disparity, suggesting the importance of reducing individual 
payment and providing easy access to promote equality of cervical cancer prevention. 
In conclusion, this thesis confirms the overall effectiveness of cervical screening in preventing 
invasive cervical cancer, addresses specific questions regarding unsatisfactory prevention for 
cervical adenocarcinoma and cervical cancer in older women, as well as identifies suboptimal 
aspects in screening for further investigation. It optimises the audit framework as an evaluation 
tool for screening programme quality assurance, and provides a benchmark for future 
comparisons with new screening practices. The thesis also verifies the role of delivery mode of 
HPV vaccination on reaching high and equal uptake of the vaccine, bolstering the hope of 
ultimate elimination of cervical cancer.  
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1 INTRODUCTION 
Cervical cancer is the fourth most common cancer among women worldwide (1), and is 
acknowledged as the first cancer able to be effectively prevented. The Papanicolaou (Pap) 
smear test, being invented in the first half of 20th century, detects not only the malignancy but 
also pre-malignancies of the cervix by reading morphology of exfoliated cells under the 
microscope. The detection and treatment of pre-malignancies prevent them from progressing 
to invasive cervical cancer. Cervical screening using Pap test, therefore, becomes the secondary 
prevention approach. In recent decades, through the discovery of human papillomavirus (HPV) 
in carcinogenesis, aetiology of cervical cancer became better understood, and the prophylactic 
vaccine against the two main oncogenic types of HPV was consequently developed as the 
primary prevention approach. More recently, screening through detecting high-risk HPV, 
which has better sensitivity, was widely implemented, and the vaccine protecting against nine 
types of HPV, which causes 90% of cervical cancer, emerges. 
There have been great achievements in cervical screening over five decades of implementation. 
The age-standardised incidence rate of cervical cancer decreased substantially in countries 
performing high-quality cervical screening programme (2). In Nordic countries, nearly half of 
cervical cancer cases were believed to have been prevented (3). Evidence from individual-level 
data also supported the existence of the cancer-preventive effect of cervical screening (4–6). 
Nevertheless, the effectiveness of cervical screening remains uncertain in some specific aspects, 
with the second common histopathological type of cervical cancer, adenocarcinoma, not 
experiencing evident incidence decline over past decades (7). The cytological abnormality 
“atypical glandular cells” found in screening, which denotes cellular changes of the same type 
of cells giving rise to adenocarcinoma, has not been comprehensively investigated regarding 
the long-term risk for cervical cancer and the status of following management. The conspicuous 
incidence in women above age 60 years (3) led to debates about the effectiveness of cervical 
screening at older ages, and the appropriate age and criteria to discontinue cervical screening.  
High efficacy and effectiveness of HPV vaccines in preventing precursor lesions of the cervix 
have been repeatedly reported (8–11). It is anticipated that the inadequate coverage of the 
vaccination could lead to inequality in cervical cancer development between the vaccinated 
and unvaccinated individuals. Approaches to promote HPV vaccine uptake and reduce 
disparities, therefore, need to be investigated. 
Entering the next 50 years for cervical cancer prevention, having the ambition to eliminate the 
disease is no longer impossible. To achieve the goal, improving effectiveness and pursuing 
high and equal uptake of preventive approaches are essential. Sweden is one of the countries 
with unique opportunities to facilitate the desired improvements with evidence not only due to 
the long history of screening practice and the pioneering introduction of the vaccine, but also 
the abundant resources of individual-linkable registers covering the entire population. This 
thesis, therefore, aimed to perform an in-depth evaluation of the effectiveness of cervical 
screening, and investigate the social disparity of HPV vaccine uptake, utilising population 
register data in Sweden.  
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2 BACKGROUND 
2.1 CERVICAL CANCER 
Cervical cancer is the carcinoma developed on the epithelium of the cervix. There are two types 
of epithelium on the cervix, squamous epithelium formed by multi-layer squamous cells on the 
ectocervix, and glandular epithelium formed by single-layer columnar cells on the endocervix. 
The area that the columnar cells transform to squamous cells (so-called squamous metaplasia) 
is called transformation zone, at where cervical cancer usually arises. The most common 
histopathological type of cervical cancer is squamous cell carcinoma originating from 
squamous epithelium. The second common one is adenocarcinoma originating from glandular 
epithelium.  
Human papillomavirus (HPV) is believed to be the necessary but not sufficient cause of 
cervical cancer (12). So far, the HPV family has more than 170 known types, and more types 
are continuously found (13). More than 40 types of HPV can cause infection in the genital tract, 
and 15 types were recognised as high-risk types associated with cervical cancer carcinogenesis 
(14), of which HPV 16 and 18 causes around 70% of cervical cancers. HPV is ubiquitous, and 
the infection is not uncommon in population since its global prevalence found in cytologically 
normal samples are around 12% (15). However, 90% of HPV infections are transient and can 
be cleared spontaneously by the immune system in one to two years (16). Very few infections 
with high-risk HPV persist and lead to progression to cervical cancer. Carcinogenesis is caused 
by gene E6 and E7 of the virus which express oncoproteins that inhibiting tumour suppression 
proteins p53 and pRB, respectively (17).  
Cervical cancer development can take fifteen to twenty years from HPV infection (16). The 
persistent infection causes cellular change and abnormal proliferation of epithelial cells which 
poses lesions. Typical progression to squamous cell carcinoma starts with the virus accessing 
the basal cells of the cervical epithelium and promote transformation and abnormal growth of 
squamous cells, known as cervical dysplasia. The severity of the dysplasia increases as the 
transformed and abnormally growing cells forms lesions involving from partial to all layers of 
epithelium, and the virus DNA from presenting and replicating by episomal state to integrating 
to host chromosomes. Once the dysplasia breaks the basement membrane, the invasive cervical 
cancer is developed (18). The severity of dysplasia is indicated by a well-defined spectrum, 
named cervical intraepithelial neoplasia grade 1 to grade 3 (CIN1, CIN2, CIN3) (Figure 1). 
Although dysplasia can progress from CIN1 to CIN3 and to invasive cancer, many of the CIN 
regress to normal. It is reported that the regression rates of CIN1, CIN2, CIN3 are around 60%, 
40% and 33%, and the progression rates are around 10%, 20% and 12%, respectively (19). 
However, the progression pathway of cervical adenocarcinoma and the natural history of 
glandular dysplasia remains unclear. 
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Figure 1: HPV-mediated progression to cervical cancer (From: The natural history of cervical HPV infection: 
unresolved issues, Woodman et al. 2007) 
Besides HPV infection, other external risk factors were found to be associated with cervical 
cancer development, including early sexual debut (20), high lifetime number of sexual partners 
(21), smoking (22), multiparity (23) and long-term use of oral contraceptives (24). These 
factors are believed to be associated with either the susceptibility to HPV infection or the 
capacity of the immune response to combat the infection (25).  
2.2 CERVICAL SCREENING 
2.2.1 Screening method 
2.2.1.1 Papanicolaou test 
The years of progression from pre-malignant dysplasia to invasive cervical cancer provides 
plentiful opportunities for screening. Papanicolaou smear test, which was invented in early half 
of 20th century by Greek doctor Georgios Papanikolaou before the aetiology of cervical cancer 
was known, detects the pre-malignancies as well as micro-invasive disease by sampling the 
exfoliated cells at and around transformation zone, and examining the morphology of cells 
under the microscope, thus it is also referred as cytological test. Women who are found 
cytological abnormalities from Pap smear test are referred to colposcopy, under which the 
cervical dysplasia are visible. Colposcopy-directed biopsy of the dysplasia can be taken for 
histological assessment to diagnose precursor lesions or invasive cancer. If precursor lesions 
are diagnosed, treatments to remove the lesions, including conisation, loop electrosurgical 
excision procedure, laser excision or ablation and cryotherapy, block the progression, and 
invasive cancer is therefore prevented.  
In the conventional Pap smear test process, a sample of exfoliated cervical cells is smeared on 
the microscope slide directly by hand, which can cause cells clumping thus makes the single 
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cells difficult to read. Cells can also distort if being exposed to air for too long. More recently, 
liquid-based Pap test was invented to solve the problems. It preserves the sampled cells in 
preservation solution so that the cells are immediately fixed. It also removes other contents of 
the specimen such as mucus, blood and microorganisms which may disturb the cell reading. 
Moreover, the samples slides are smeared under laboratory control, to make sure that cells are 
in monolayer which makes the cell reading much easier. Sample quality is therefore largely 
improved, and the accuracy of cytological diagnosis is increased (12,26).  
A screening test detects the status of cervical epithelial cells at a time point, but dysplasia can 
initiate afterward. In order to gain optimal “protection” from screening, regular tests with 
certain time interval are required. The interval is defined by the evidence of duration of the 
“protective” effect against invasive cancer from a negative screening test, which is 
acknowledged as three to five years for Pap test (4).  
2.2.1.2 HPV testing 
After the establishment of the aetiological link between HPV infection and cervical cancer, 
testing HPV as a screening method is rapidly developed. Since HPV infection initiates years 
before the onset of precursor lesions, use of this method allows the pre-clinical phase of cervical 
cancer to be prolonged, thus potentially increases the opportunity to detect pre-malignancies. 
Furthermore, cytological screening requires manual labour to read the sample, hence the 
sensitivity is unsatisfactory, and can vary largely between 30%-90% (27), whereas HPV testing 
provides relatively equal sensitivity which is shown to reach above 90% in detecting CIN2+ 
(28–30). Evidence also demonstrates that HPV testing does not lead to over-diagnosis but early 
diagnosis of high-grade precursor lesions, and a negative test result can provide longer 
“protection” than normal test result from the cytological test (31–33), which implies potential 
of prolonged screening interval.  
Given the advantages, HPV DNA testing is gradually implemented as the primary screening 
technique replacing cytology in some countries, usually with cytology as a triage method for 
HPV positivity. Discussions and research are ongoing regarding the optimal ages of 
implementation and triage strategy.  
2.2.2 Opportunistic and organised cervical screening  
Cervical screening can be performed opportunistically or through organisation. Opportunistic 
screening requires women’s own initiative to seek the screening service, whereas in organised 
screening women are invited by the organiser to take a planned test. Organised screening is 
more effective than opportunistic screening in several aspects: the organisation with invitation 
manner achieves higher coverage and more equal participation (34); since the interval of 
screening is regulated by the organiser based on evidence, the optimal protection is assured and 
over-screening is avoided, thus gains greater cost-effectiveness; quality assurance examined by 
the organiser further ascertains the high-quality practice over time.  
  5 
2.2.3 Cervical cancer incidence worldwide in relation to screening 
implementation 
Cervical cancer used to be the second most common cancer among women worldwide (35), 
while has now been down to the fourth one (1). Strong success of cervical screening was 
reflected by the changes in cervical cancer incidence worldwide in the past fifty years. A 
remarkable downward trend of cervical cancer age-standardised incidence rates (ASRs) is 
observed in countries performing cervical screening (2). However, the ASRs kept stable or 
even increased in countries where screening was absent (2). A substantial decrease of cervical 
cancer incidence was observed in Nordic countries including Sweden, where national 
organised cervical screening programmes are well implemented (2,3). It was estimated that 41-
49% of cervical cancer cases had been prevented by the screening since the 1960s (3). 
Nowadays, the disease burden varied largely between low- and high-income countries, with an 
estimation of 85% cervical cancer cases occurring in less developed regions, where in some 
areas it remained the most common cancer among women (36). 
2.2.4 Cervical screening programme in Sweden 
Screening using Pap smear test was initiated in Sweden in 1964, and organised cervical 
screening programme was successively implemented in counties during 1967-1977 (37). Each 
county, as the autonomic screening organiser, invites women regularly to take screening test in 
nearby maternity care centres. The Swedish National Board of Health and Welfare  issues the 
national recommendations for cervical screening. The recommendation established in 1985 
proposed cervical screening being performed in women aged 20-59 every three years, and the 
recommendation in 1998 revised the starting age to 23, proposed a three-year interval for 
women aged 23-50, and five-year interval for women aged 50-60. As counties/regions have 
autonomy in screening organisation, variations in actual performance exist in terms of age-
ranges and invitation procedures (38). Nevertheless, the coverage of cervical screening 
increased gradually all over the country during the past 50 years. By 2016, 82% of women in 
Sweden have participated in screening in the recent screening round, and around 70% of the 
screening tests were organised tests (39).  
Up to the end of 2016, cytology was used as the primary test, with liquid-based cytology being 
gradually introduced since the early 2000s. In mid-2015, the recommendation for switching to 
HPV-primary screening was issued. Women aged 23-29 were recommended to keep cytology-
primary screening to avoid over-diagnosis, and women aged 30-64 were recommended to have 
HPV-primary screening with cytology triage, under 3-year (age 30-49) or 7-year (age 50-64) 
interval. The implementation started in two counties at the beginning of this year, 2017. 
Clinical management of abnormal screening results for a long time followed guidelines issued 
by each county/region, which are similar to or different from the national recommendations 
established by Swedish Society of Obstetrics and Gynaecology in 1983, 1997 and 2010. In 
order to promote equal prevention of cervical cancer over the entire country, Regional Cancer 
Centres jointly established a national guideline in 2015, and agreed to follow this guideline in 
their own counties/regions.  
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2.2.5 Issues to be addressed 
2.2.5.1 Weaker prevention for cervical adenocarcinoma by screening 
Cervical adenocarcinoma is the second most common histological type of cervical cancer. 
During the past decades, as opposed to the dramatic decrease of the dominant type squamous 
cell carcinoma (SCC) (40,41), the incidence of adenocarcinoma experienced a different trend 
worldwide. Countries including US, Canada, UK, and almost all Nordic countries observed a 
constant increase in incidence of cervical adenocarcinoma mainly up to 1995 (42–45). 
Thereafter, several of these countries reported a plateau or slight decline (41,44,46–48) in 
incidence rates. Consequently, adenocarcinoma has accounted for close to or more than 20% 
of cervical cancer cases in countries with declined SCC (5,49,50).  
Adenocarcinoma and SCC share most of the risk factors with a few discrepancies. A 
collaborative study showed that a positive test for cervical high-risk HPV-DNA was a strong 
risk factor for both histological types (51). HPV types 16 and 18 are found to be strongly 
associated with adenocarcinoma (52), where HPV 18 are more commonly found in 
adenocarcinoma than in SCC (53–55). However, it is also reported that in samples of cervical 
cancer cases, adenocarcinoma has lower positivity of HPV DNA (62%) than SCC (87%) (54). 
Other risk factors for adenocarcinoma are similar to those for SCC: increasing number of sexual 
partners, younger age at first intercourse, increasing parity, younger age at first full-term 
pregnancy and increasing duration of oral contraceptive use, with the only exception of 
smoking (51).  
Given the similar risk factors to SCC, the opposite trend of incidence of adenocarcinoma raised 
the question about the effectiveness of screening on preventing this histological type of cervical 
cancer. An Australian case-control study published in 1995 initially found there was no 
significant difference between adenocarcinoma cases and controls in the number of negative 
cytology reports, or in history of cervical abnormality (56). But others argued that there must 
be ample time for screening for pre-invasive lesions, as they found a 13-year difference 
between the mean age of adenocarcinoma in situ (AIS) and invasive adenocarcinoma (50). 
Larger studies in the recent decade did find a tendency of preventing effect of screening against 
adenocarcinoma (49,57–59). Liquid-based cytology using ThinPrep Pap test may have 
contributed to it since it provided better detection of glandular lesions (60). This may have led 
to the non-increasing incidence of adenocarcinoma since 1995. Moreover, screening was 
shown to prevent advanced invasive adenocarcinoma (49) thus reduced mortality (61). 
Nevertheless, the magnitude and duration of the effectiveness are agreed to be far less than that 
for SCC (49,57,59). Uncertainty remains about whether the inferior effectiveness resulted from 
the low accuracy of Pap test, insufficient management of detected abnormalities, or both. 
2.2.5.2 Uncertain risk of cervical cancer following atypical glandular cells found in Pap 
test 
“Atypical glandular cells” (AGC) is a type of cytological abnormality found in Pap test, 
denoting the morphological changes of glandular cells, but lacking the features of 
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adenocarcinoma in situ or invasive adenocarcinoma in the cervix uteri. AGC is an uncommon 
finding that generally comprises less than 1% of the population (39,62). The terminology is 
defined and modified by the Bethesda System (TBS), a guideline for reporting cervical/vaginal 
diagnosis. The TBS issued in 1988 recommended “atypical glandular cell of undetermined 
significance” (63). In 1991, it recommended that a further qualification whether a reactive or a 
premalignant/malignant process is favoured (64). In order to avoid confusion with atypical 
squamous cells of undetermined significance (ASCUS), it was changed to “atypical glandular 
cells” in the 2011 revision. The category “favour reactive” was simultaneously removed (65). 
Sweden has only used “atypical glandular cells” without subcategories. 
AGC can signify a group of conditions, from benign findings such as reactive changes or 
polyps, to severe dysplasia or even cancer (66). The former term “atypical glandular cell of 
undetermined significance” made it appear to be the counterpart of ASCUS, thus was 
considered as a finding meaning low risk for malignancy. However, studies on the clinical 
significance of AGC found a high proportion of existing premalignant or malignant lesions. 
Schnatz et al (62) reviewed 24 studies and found that approximately 1.5% of AGC were 
confirmed to have underlying cervical malignancy at or shortly after diagnosis, 2.9% were 
adenocarcinoma in situ, 8.5% were low-grade squamous intraepithelial lesions, and 11.1% 
were high-grade squamous intraepithelial lesions. Besides cervical lesions, they also found 
4.1% other malignancy including endometrial adenocarcinoma, ovarian and fallopian tube 
carcinoma and others. This indicates that more than 20% of AGC require further attention and 
more than 15% of them are severe. The majority of studies included in this review contained 
small number of AGC smears restricted to one clinic or region, and had only short term follow-
up. A population-based study including more than 8000 women with AGC found an 18-fold 
higher risk of incident cervical cancer in an average follow-up of 6 years after AGC, compared 
to the general population (67). But the risk profile compared to HSIL or LSIL was not 
investigated. 
Specifically, for the histological type of cancer associated with AGC, studies found 0.6%-3% 
of invasive adenocarcinoma of the cervix at or shortly after AGC (68–75), but are limited with 
only 1 to 7 cases of cervical adenocarcinoma and could thus not analytically confirm the 
association between AGC and adenocarcinoma. Some studies have investigated the age pattern 
of malignancies related to AGC. Results were partially conflicting about whether neoplasia is 
more common in young women than older, or vice versa (70,71,76–79). 
The clinical management for AGC has been a dilemma as the research of the risk profile are 
limited due to the rarity of AGC (78). Based on the collective evidence on clinical significance, 
the American guidelines recommend initial workup for all AGCs using colposcopy with 
endocervical sampling, and endometrial sampling for women aged above 35 years, and follow-
up at 6 months or 12 months depending on HPV status (80). One study has investigated the 
effectiveness of management arms after cytological finding of AGC and did not reach any 
conclusive result due to low statistical power (81). 
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2.2.5.3 Relatively high incidence of cervical cancer among older aged women 
Cervical cancer is acknowledged to develop mainly in midlife. In 1960s-1970s, incidence of 
cervical cancer peaked at ages before 50 years in majority of European countries, and declined 
rapidly or gradually afterwards (82,83). However, in recent one to three decades, many 
countries observed a second peak of cervical cancer incidence after age 60 (2,84), and more 
than one third of annual cases came from women aged 60 or 65 above, which were also detected 
at more advanced stages (5,6).  
The reason behind this age feature was discussed from aspects of biological and screening 
effect. Early study reported a decline prevalence of HPV over age (85), while recent 
investigations from some other settings found a bipolar shape of HPV prevalence where the 
prevalence in postmenopausal ages was higher than in reproductive ages (86,87). The high 
prevalence was recognised to be a result of longer persistency or re-emergence of latent 
infection (17), since the new infection was found decreased at older ages (86,88,89). The 
latency or re-emergence were believed to be due to the degenerated immune system at older 
ages (17,90), and possibly the use of hormone replacement therapy (91). The effect of cervical 
screening for older aged women was long been questioned. The initial arguments against 
screening in this age group were based on the natural history studies, that the incidence and 
prevalence of abnormality or precursor lesion was found remarkably lower among women aged 
50 and above (92–95), which was believed to be due to the unreliability (higher false-negative) 
of the Pap smear test, namely that the adequate sampling of representative cellular material at 
the transformation zone is more difficult to obtain for postmenopausal women since the zone 
tends to migrate inward to the endocervix as women aged (96,97). Yet there was also opposite 
finding that the prevalence of CIN3 was comparable with younger women (98). In recent 
decades, population-based evidence demonstrated significant cancer-preventive effect of 
cervical screening at older ages. A Swedish study found an odds ratio of 0.36 for the protective 
effect from the past screening for women aged 66 and above (5). A Finnish study found a 51% 
risk reduction from the screening invitation between ages of 65 and 69, and a 34% risk 
reduction of the invitation at the age of 65 for a follow-up up to 19 years afterwards, although 
not statistically significant (6). A UK study found that women with adequate negative screening 
at age 50–64 had 86% reduced risk of cervical cancer at age 65–83 compared with women who 
were not screened (99).  
Given the evidence of effectiveness, countries started to elevate the upper aged limit of cervical 
screening to cope with the substantial cervical cancer cases in older aged women (99–101). 
However, age and criteria to discontinue cervical screening remains unclear. A recent study 
investigating the incidence of cervical cancer in elderly by birth cohort showed that, the high 
incidence was only observed in older birth cohorts which had poor life-time screening history 
(102). It implied the necessity of considering screening history when designing and evaluating 
the screening in older aged women. This issue was addressed by one modelling study, which 
demonstrated that continued screening after age 65 provides little additional benefit on 
incidence and mortality among women screened with cytology every 3 years before age 65 
(103). One exemplary empirical data reported risk for dysplasia after age 50 in relation to the 
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screening history before age 50 years (104). More empirical data for even older ages is in 
demand.  
2.3 HPV VACCINATION 
Development of HPV vaccine emerged since the recognition of HPV causing cervical cancer. 
The current commercial prophylactic vaccines contain virus-like particles (VLPs) which are 
assembled from recombinant HPV capsid protein L1. Once injected, immune response is 
triggered by the VLPs and enhanced by an adjuvant. Since no HPV DNA is included, the 
vaccines have no risk for virus infection (105). Two vaccines were approved internationally 
including European Medical Agency (EMA) in 2006-2007, which are the bivalent vaccine 
CervarixTM developed by GlaxoSmithKline protecting against HPV 16 and 18, and 
quadrivalent vaccine GardasilTM developed by Merck protecting against HPV 6, 11, 16, and 
18. HPV 16 and 18 are the high-risk types causing 70% of cervical cancer, whereas HPV 6 and 
11 are low-risk types causing genital condyloma. In 2015, Gardasil9TM which protects against 
five more high-risk HPV types was authorised by EMA. The five types are HPV 31, 33, 45, 52 
and 58 which cause around 20% of cervical cancer. Therefore, in total, 90% of cervical cancer 
are expected to be prevented by the nine-valent HPV vaccine. 
Given the strong efficacy of the vaccine before exposure to HPV, the vaccines are 
recommended to be given to people from 9 years of age, as early as possible. The vaccines 
were initially licensed with a 3-dose-schedule, at the months 0, 1, 6 for the bivalent vaccine, 
and at the months 0, 2, 6 for the quadrivalent vaccine. Since studies found non-inferior effect 
from two doses in immune response and HPV 16/18 infection among the lowest eligible ages, 
in 2014, World Health Organisation recommended a two-dose-schedule for people aged 9-14, 
at the 0 and 6th month (106). 
2.3.1 Efficacy, effectiveness and safety 
Robust efficacy and effectiveness of the vaccines, from clinical trials and real-population data, 
have been accumulatively reported. Clinical trials showed a higher immune response after the 
vaccination compared to nature HPV infection in terms of serum antibody concentration (107–
109), and an 90%-100% efficacy for the short-term endpoints such as genital condyloma and 
HPV 16 and 18 related CIN1 (110), as well as longer-term endpoints of CIN2+ (111). Several 
years since the introduction of quadrivalent vaccine in some countries, the incidence of genital 
condyloma in the population declined dramatically (112,113). In recent years, evidence from 
population data demonstrate an effectiveness of 75% against CIN2+ in those vaccinated before 
age 17 years (11). Meanwhile, evident herd immunity was also shown, that the HPV 16 and 18 
infection, incidence of condyloma exhibited decline trend in the unvaccinated population (114–
116). 
Although intense attention was paid on various adverse events happening after the vaccination, 
clinical trials and postlicensure monitoring found that apart from injection-site symptoms, 
headache and fatigue which were transient, no difference of severe adverse was observed 
between vaccinated (intervention) and unvaccinated (control) group (117–120). Rigorously 
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designed population-based studies demonstrated that no severe adverse events, such as 
autoimmune and neurological diseases (121,122), adverse pregnancy outcomes (123) can be 
attributed to the vaccination, since the incidence of those events in vaccinated population was 
not different from the unvaccinated population. Even no evidence of increased new-onset 
autoimmune diseases observed when the vaccine was given to girls having pre-existing 
autoimmune disease (124).  
2.3.2 Socioeconomic factors associated with HPV vaccine uptake 
Socioeconomic factors has been approved to be associated with health care utilisation including 
the participation in disease preventive programmes, as it affects both access and adherence to 
the interventions (125–128). It is agreed that generally people of lower socioeconomic status 
use fewer health services. The explanation of this phenomenon may fall into three categories: 
financial access or affordability differences; knowledge and attitudinal differences regarding 
care-seeking; and health care system factors in terms of the organisation or response (129). 
Before the introduction of HPV vaccine, studies about people’s attitude towards the vaccination 
had revealed disparities on certain socioeconomic factors. Parents’ ethnicity, education, 
employment status, and disposable family income were found to be associated with their 
willing to vaccinate their adolescent children (130,131). Similar factors were also reported to 
be associated with HPV vaccine acceptance in young adults (132–134). A highlighted finding 
was that higher education was usually associated with lower willingness to vaccinate (131–
134). After initiation of the vaccination, disparities in HPV vaccine uptake was investigated in 
various settings. It was generally reported that girls/adolescences born outside the resident 
country or with foreign-born parents had lower vaccination uptake (135–137). Level of income 
was positively associated with vaccine uptake (137–141). The role of education was in 
discrepancy, with some studies reported positive association between parental education and 
girls’ uptake (137,140), and some studies revealed similar scenario as the attitude studies that 
higher educated parents vaccinated their daughters less (141–143).  
The impact of delivery strategy of HPV vaccination was investigated by a literature review 
comparing the coverage of HPV vaccination across settings with different delivery strategies. 
It found that school-based delivery usually presented higher coverage (144). The 
socioeconomic differences of HPV vaccine uptake in relation to delivery strategy was 
examined in Canada and Belgium, which reported decreased association between vaccine 
uptake and socioeconomic status/family income in the school-based delivery (145,146). In 
these studies, socioeconomic factors were assessed in group level or with single indicator. More 
comprehensive evidence is needed. 
2.3.3 HPV vaccination in Sweden 
HPV vaccine was introduced in Sweden in 2006. In May 2007, the cost of vaccination became 
subsidised by government for girls aged 13-17 years. The subsidy was included in the national 
healthcare system, meaning that the cost of HPV vaccination, together with other costs of 
prescriptive medications of each person, was subsidised by the government when exceed the 
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limit for personal payment (1800SEK by December 2011, approx. 180 euro) in 12 months, 
which was for up to 50% of the price of HPV vaccine. Quadrivalent vaccine was accounted for 
99% of all HPV vaccination. Girls/parents requested the vaccination opportunistically from 
primary healthcare givers or vaccination centres.  
HPV vaccination was introduced to the National Immunisation Programme in 2010 for girls at 
primary target ages, i.e. 10-12 years. It requires the vaccination to be fully financed by the 
government and be given in schools. Therefore, in January 2012, a free-of-charge school-based 
vaccination was initiated for girls born in 1999-2001, together with a free-of-charge catch-up 
vaccination delivery targeting girls born in 1993-1998 (147). Since 2013, the successive birth 
cohorts reaching primary target ages were targeted in school-based vaccination, and the catch-
up vaccination was offered to girls up to age 18 years in typical implementation. Unlike the 
school-based vaccination for primary target ages, the catch-up vaccination was administrated 
in various settings in different counties. Among the 21 counties in the nation, 9 administrate in 
primary healthcare centres or vaccination centres, 4 in schools, and 7 in both, according to an 
investigation (147). Between 2014 and 2016, two counties implemented the catch-up 
vaccination up to age 26 years. Quadrivalent vaccine was offered in the school-based and catch-
up vaccination. 
The three-dose-schedule was initially administrated. In 2015, the two-dose-schedule was 
implemented for the primary target group in school-based vaccination.  
By the end of 2016, the coverage of HPV vaccination in Sweden exhibited evident diversity 
across birth cohorts eligible for different vaccination delivery modes (Figure X).  
Figure 2: coverage of HPV vaccination in girls or young women by birth cohort, by 31 December 2016 (From 
Sparén, 2017) 
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3 AIMS 
The overarching aim of the thesis was to use epidemiological approaches to evaluate the 
effectiveness and weaknesses of cervical screening program from panorama to focal points, 
and investigate the role of delivery design on pursuing equality of HPV vaccination.  
The specific aims of studies were: 
 To examine the overall effectiveness and imperfection of cervical screening program 
with stratification of histopathological type in a case-control audit frameword (Study 
III) 
 To investigate the long-term risk of cervical cancer, especially adenocarinoma, 
following atypical glandulcar cells found in cervical screening, and compare the risk 
and following assessment to squamous intraepithelial neoplasia (Study I). 
 To examine the effectiveness of cervical screening after age 60, stratefied by screening 
history at ages 51-60 (Study II) 
 To assess the social disparity of HPV vaccine uptake by delivery mode of the 
vaccination (Study IV) 
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4 RESEARCH APPROACHES 
4.1 DATA SOURCE 
4.1.1 ACCES database 
Advancing Cervical Cancer Eradication Strategies (ACCES) database was established in 2006 
for research of cervical cancer prevention. It was built based on the Swedish National Cervical 
Screening Registry (NKCx). To obtain related information about all women targeted for 
screening, NKCx was linked with the Swedish population and healthcare registers, retrieving 
information regarding demography, cervical cancer, cause of death, hospital care (including 
surgeries), childbirth, socioeconomic circumstance, etc. These data were held by two 
government agencies, Statistics Sweden (Statistiska centralbyrån, SCB) for population 
registers, and the National Board of Health and Welfare (Socialstyrelsen) for healthcare 
registers. Information on HPV vaccination since 2006, which were held by Public Health 
Agency of Sweden (Folkhälsomyndigheten, FoHM) and its predecessor, was also added to the 
database. 
All of the studies in this thesis used information in the ACCES database. Information involved 
was listed in Table 1 and described below. 
Table 1: overview of registers used in this thesis 
Content Register Source Study 
Cervical screening The Swedish National Cervical Screening Registry NKCx I, II, III 
Cervical cancer The Swedish Cancer Registry Socialstyrelsen I, II, III 




HPV vaccination Prescribed Drug Register (PDR) Socialstyrelsen IV 
Swedish Vaccination Register (SVEVAC) FoHM IV 
National Vaccination Register (NVR) FoHM IV 
Population Total Population Register SCB I-IV 
Migration I-IV 
Multi-generation IV (II, III) 
Hysterectomy The Swedish Patient Register Socialstyrelsen I, II, III 
Death The Swedish Cause of Death Register Socialstyrelsen I-IV 
Education Longitudinal integration database for health 
insurance and labour market studies 
SCB II, III, IV 
Income IV 
 
4.1.2 Description of registers 
The Swedish National Cervical Screening Registry (NKCx in Swedish acronym) 
Since the introduction of cervical screening in late 1960s, the individual counties in Sweden 
have organised and implemented cervical screening autonomously (38), and started digital 
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records of screening test successively. In 2002, NKCx was built with aims of nationwide 
documentary, evaluation and surveillance of cervical screening program. It collects the digital 
records of screening related information over Swedish counties, including all organised and 
opportunistic screening tests, histological tests, and invitations to screening. The coverage of 
cytology tests increased gradually since 1970s, and reached closed to 100% in 1995 (Figure 3). 
Histology test records reach the full coverage in 1993. The invitation records started in 1990s 
and completely nationally since 2006. 
Figure 3: Time of initiating cervical screening records by counties/hospitals 
Swedish Cancer Registry 
The Swedish Cancer Registry was founded in 1958. The recording is based on compulsory 
reporting of newly detected cancer by health care providers over the entire country, and 
subsequently verified and corrected by six regional cancer registers. Information of tumour 
sites, histological type, date, place of diagnosis, etc. are recorded (148). It has been verified that 
the completeness of the register is high enough to leave out major impact for most uses of 
epidemiological studies (149). 
The National Cervical Cancer Audit Database 
The national cervical cancer audit aims to provide quality control indicators for an optimal 
cervical screening program, by performing standard analyses of the association between 
cervical screening and cervical cancer development in a case-control framework. The present 
audit database comprises cervical cancer cases diagnosed in Sweden during 2002-2011. The 
cancer cases were originally identified from Swedish Cancer Registry, and subsequently 
underwent thorough clinical and histological review. The clinical review went through each 
cancer case’s original medical charts stored in regional hospitals, verified and complemented 
crucial information of the cancer diagnosis. The histological review re-evaluated the 
histopathology of 91% of cancer cases by reading the sample slides collected from pathological 
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laboratories all over the country. After the review, those who were not cancer of cervical origin, 
not epithelial, not primary cancer, and recurrent cancer were excluded. 
Registers for HPV vaccination 
Since HPV vaccine was on market in Sweden in 2006, three registers have been involved in 
recording the vaccination. From 2006-2012, it was recorded primarily in Swedish Vaccination 
Register (SVEVAC) (150). At the same time, the vaccinations were also recorded in Prescribed 
Drug Register (PDR), since the vaccine needs to be prescribed by clinicians in order to receive 
reimbursement. PDR records drug prescriptions for outpatient care in the entire country. Since 
the start of school-based vaccination in January 2012, the PDR does not record the school-
based and catch-up HPV vaccination, as girls received the vaccine directly at school or 
vaccination centre without prescription. However, as SVEVAC is a voluntary reporting register 
around 25% of the vaccinations were without the identity of girls, i.e. being anonymous 
vaccinations that unable to link with other registers. In 2013, a compulsory reporting register 
for childhood vaccinations, National Vaccination Register (NVR), was initiated. Since then, all 
school-based HPV vaccination was registered with identity. 
Total population register 
The church of Sweden has kept a register of the population of Sweden since the 17th century. 
In 1968, after a large proportion of data were computerised, the Total Population Register (TPR) 
started. It records a large scope of individual information of all Swedish residents, from date 
and country of birth, place of residence, marital status, to migration record (both immigration 
and emigration), and multi-generation relationships (151).  
Cause of Death Register 
The Swedish Cause of Death Register records all deaths of people registered in Sweden. The 
computerised annual-updated registration started in 1961, yet the records from 1952 to 1960 
were compiled retrospectively. The register contains information of death date, place, the 
underlying and contributing reasons of death denoted with International Statistical 
Classification of Diseases and Related Health Problems (ICD) codes, etc. Validation study 
shows a high completion and quality of the register (152). 
Patient Register 
The Swedish Patient Register was established in 1964. It started by recording information of 
patients discharging from inpatient care, including personal related information, date of 
admission and discharge, primary and additional diagnoses, surgery procedure, etc. It did not 
reach nationwide completion until 1987. In 2001, it began to include records of hospital-based 
outpatient care (153). In this thesis work, the surgery of total hysterectomy was obtained from 
the Patient Register. As total hysterectomy was performed in inpatient care, the information 
was available since 1964 and complete since 1987. 
LISA database 
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Longitudinal integration database for health insurance and labour market studies (LISA by 
Swedish acronym) contains a great amount of information of individual from the labour market, 
educational and social sectors, as well as the relative relations with their families and employers. 
The database holds annual registers since 1990, covering all Swedish residents aged 16 and 
above (154). Education and family disposable income was used in this thesis work. 
4.2 ETHICAL CONSIDERATION AND DATA LINKAGE 
Swedish law regulates the use of individual-based register data for research. According to its 
provisions, informed consent from individuals in the registers is not required, yet the ethical 
approval of the research aim and protocol granted by an ethical review board is prerequisite 
(155). The ACCES database received ethical approvals from the regional ethics committee in 
Stockholm, Sweden. The studies in this thesis involved approvals of Dnr 02-556, Dnr 
2011/921-32, Dnr 2012/216-32, Dnr 2011/1026-31/4.  
Once ethical approval was granted, the requested data were extracted from registers held by 
each agency. SCB gathered all data and conducted the data linkage on the individual basis via 
personal identification number (PIN). PIN is assigned by the Tax Agency in Sweden for all 
citizens and inhabitants who intend to live in Sweden for at least one year, and is used as 
identity indicator in numerous aspects of personal and social. Therefore, to protect integrity of 
registered individuals, SCB replaced PIN with randomly generated sequence number when 
sending the linked data to researchers. Even though, the linked data remains under secrecy, 
because theoretically individuals are still identifiable backward by combining information in 
the data. The use of the individual-level research data is therefore under strict management to 
avoid any leakage or illegal dissemination. 
4.3 MAIN MEASUREMENTS 
4.3.1 Cervical screening status and cytological classification of the result 
Any Pap test record in NKCx in certain study period can be considered as being screened, 
which means organised and opportunistic screening tests are both included when defining 
screening status. However, since the register of screening did not complete nationwide before 
1995, no screening record in the register did not necessarily indicate that no screening was 
performed before the initiation of screening register in certain county. This issue particularly 
affects study III where the study population was the older birth cohorts, and their screening 
history since age 51 was prerequisite. To avoid misclassification of screening status, we 
excluded women living in the counties where cervical screening records were not initiated 
before they turned 51 years of age. For the remaining women being included in the study 
population, no record in the register during the defined study period was considered unscreened. 
Result of Pap test is the key information in study I, II, and III. It was originally recorded by 
regional laboratories, which analysed the smears, in varied coding systems. After collecting 
data, NKCx translated the codes into the uniform SNOMED (Systematised Nomenclature of 
Medicine) coding system defined by Swedish Association for Clinical Cytology. 
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The result of Pap test was classified into: low-grade abnormality, if women had ASCUS 
(atypical squamous cells of undetermined significance) or mild squamous dysplasia; and high-
grade abnormality, if women had moderate or severe squamous dysplasia, atypical cells of 
uncertain origin, adenocarcinoma in situ, cytological implication of squamous cell carcinoma, 
adenocarcinoma, or malignancy of uncertain origin. According to the finding of study I, 
atypical glandular cells were classified as high-grade abnormality in study II and III. 
Table 2. SNOMED codes for cytological diagnoses in the study, defined by the Swedish Association for Clinical 
Cytology 
Cytological diagnosis SNOMED code 
Normal cytology M00110 
Low-grade abnormalities  
Atypical squamous cells of undetermined significance  M69710 
Mild squamous dysplasia M74006 
High-grade abnormalities  
Suspected high-grade squamous dysplasia M69719 
Moderate squamous dysplasia M74007 
Severe squamous dysplasia M80702 
Atypical glandular cells M69720 
Atypical cells of uncertain origin M69700 
Squamous cell carcinoma M80703 
Adenocarcinoma/Adenocarcinoma in situ M81403 
Pap tests recorded in NKCx can be either screening tests that were performed in asymptomatic 
women, or diagnostic tests when women having symptoms suspicious for cervical cancer. The 
indication of the test is not recorded in the register, but can be speculated by time of the cancer 
diagnosis following the Pap test. Presence of suspicious symptoms leads to prioritised analysis 
of the Pap test thus accelerating the whole diagnostic process to usually within around one 
month. The analysis of asymptomatic Pap test usually takes three months, and the following 
diagnostic workup triggered by that abnormal test usually takes one to three months. This time-
frame was verified in the National Cervical Cancer Audit Database including cancer cases in 
2002-2011, in which the mode of detection (i.e. screen-detected or symptomatic cancer) were 
collected from the medical chart (Figure 3). If the Pap test was performed due to symptoms but 
no cervical cancer was diagnosed after that, the Pap test would serve similarly as a screening 
test, i.e. confirm normal cervical tissue or detecting precursor lesions, thus can be considered 
as a screening test. We therefore believe that using a time frame of around one month between 
the Pap test and cervical cancer diagnosis can distinguish diagnostic tests from screening tests. 
In study II when specifically assessing the impact of screening at ages 61-65, we verified the 
time frame between cancer diagnostic date and the first abnormal Pap test results within one 
year prior to cancer diagnosis, among cancer cases diagnosed at ages 61-65 during 2002-2011. 
The mode of detection of cases in 2002-2011 was derived from medical charts. We found that 
50-day was a reasonable time frame to differentiate symptomatic cancer from screen-detected 
cancer. 
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Figure 4: distribution of months between the first abnormality in the past year and cervical cancer diagnosis 
4.3.2 Biopsy and histological assessment of cervix tissue 
Taking biopsy under the colposcopy for histological diagnosis of cervical disease is one of the 
standard procedures following certain abnormal findings in Pap test. Determining whether one 
should take the biopsy and the method by which depends on the clinical guideline as well as 
colposcopists’ assessment regarding the type of cytological abnormality, the visual lesion 
under colposcopy, characteristics of women, etc. The histological diagnosis of the disease 
determines further management and treatment. Thus taking a biopsy is key in the process of 
cervical cancer prevention. In study I, we identified women who had histological tests of 
cervical samples performed within six months following the initial abnormality as being 
biopsied. In study III, being biopsied was defined as having histological tests within one year 
following the initial abnormality. The different design in time span was due to study purpose.  
4.3.3 Invasive cervical cancer 
Diagnosis of invasive cervical cancer in study I and II was retrieved from National Cancer 
Registry, with ICD-7 (international statistical classification of diseases, seventh revision) code 
“171”. The histological type of cervical cancer was classified in to squamous cell carcinoma 
and adenocarcinoma by the WHO/HS/Canc/24.1 histology code for anatomical location (156). 
Study III utilised the National Cervical Cancer Audit Database which included verified 
invasive cervical cancer cases in 2002-2011. Date and place of diagnosis, FIGO stage 
(International Federation of Gynaecology and Obstetrics staging system), and mode of 
detection (i.e. screen-detected or symptomatic cancer) were verified through clinical review, 
and histopathology of the cancer cases were determined by a comprehensive evaluation of the 
sources from histological review, medical chart and record in cancer registry. 
4.3.4 Total hysterectomy 
Hysterectomy, a surgical procedure to remove the uterus, is the treatment of many 
gynaecological diseases, mostly for benign conditions. It is not an uncommon surgery as 
estimations showed that one in three US women, and one in five British women will receive it 
during lifetime (157–159). In Sweden, the average age at hysterectomy was around 47-52 years 
(159). Unlike the subtotal hysterectomy that only removes the body of uterus, total 
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hysterectomy accounted for around 60% of hysterectomy surgeries for benign indications and 
involves removing the entire uterus including the cervix. Our research group found that 6.5% 
of women at age 60 years in 1983-2011 had been totally hysterectomised. Women who undergo 
a total hysterectomy will not develop cervical cancer and thus normally do not go to cervical 
screening anymore, especially if the indication of the total hysterectomy was benign. Including 
this sizable amount of women when evaluating cervical screening may introduce non-
negligible bias. Therefore, for study I, II, and III, we excluded women who had undergone a 
total hysterectomy from the study population, or we censored them during follow-up, 
depending on the research purposes. Date of hysterectomy was derived from the Swedish 
Patient Register. 
4.3.5 HPV vaccine uptake 
HPV vaccine uptake is the outcome in study IV. Girls were defined as being HPV vaccinated 
at the first dose, which was identified from the PDR, SVEVAC or NVR. In PDR, using 
Anatomical Therapeutic Chemical (ATC) Classification System codes J07BBM01 and 
J07BBM02 for the quadrivalent and bivalent vaccine, respectively. We used the date of the 
first dose of the vaccine as it indicates under which vaccination delivery mode a girl was 
vaccinated with regard to her birth year. Type of the vaccine was ignored in the study, as 99% 
of the vaccine taken before 2012 was quadrivalent, and only the quadrivalent vaccine was 
eligible for school-based and catch-up vaccination since 2012. Although SVEVAC had issue 
of anonymous vaccination, before 2012 the problem was compensated by PDR, and since 2013 
NVR offered records of school-based vaccination with identities of the girls. The anonymous 
vaccinations in SVEVAC mainly affect the school-based vaccination in 2012, and the catch-
up vaccination from 2012 to the end of follow-up which was December 2014.  
Dose completion was defined as number of time of receiving the vaccine. Each girl’s multiple 
records of vaccination in one or more registers within 14 days apart were considered as the 
same dose. 
4.4 STUDY POPULATION, DESIGN AND STATISTICAL ANALYSES 
4.4.1 Study I 
This population-based cohort study included women who lived in Sweden and had any record 
of cervical cytological test at ages 23-59 at any time from 1 January 1980 to 1 July 2011. 
Women who had a diagnosis of invasive cervical cancer or a total hysterectomy before their 
first cytology record were excluded. In total, 3,054,328 women were included in the study 
cohort. 
We extracted women’s first abnormal smear in the screening record, and classified them into 
AGC (14,625 women), LSIL (244,168 women) and HSIL (65,633 women). Women having 
been screened with normal results were defined as reference group for five years following 
each normal test. We assessed the proportion of prevalent cervical cancers which were 
diagnosed within six months following AGC and the incidence rate of cervical cancer from the 
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seventh month to 15.5 years after AGC. Using Poisson regression models, we further estimated 
the incidence rate ratio in relation to the same aged women who were screened with only 
normal results. The assessments were stratified by age at AGC, and histological type of cervical 
cancer. They were compared with the corresponding estimations following LSIL and HSIL. 
We also assessed the proportion of being followed with histology assessment from biopsy 
within six months after AGC, and the subsequent cancer incidence among the biopsied 
subgroup, comparing to the corresponding findings for LSIL and HSIL. 
4.4.2 Study II 
This population-based cohort study included 569,132 women born between 1 January 1919 
and 31 December 1945, resident in Sweden since age 51, and at age 51 or younger when their 
county of residence started to record cervical screening. Women entered the cohort when 
turned age 61. They contributed to the unscreened group before the first Pap test at age 61-65 
years, and contributed to the screened group since the first Pap test. They were followed until 
diagnosis of cervical cancer, receiving total hysterectomy, emigration, death, or the end of age 
80 years. 
We assessed the cumulative incidence of cervical cancer from age 61-80 years by screening 
status at age 61-65 years, stratified by five screening history groups at age 51-60 years, which 
were 1) adequately screened (at least two separate Pap tests) with normal results only; 2) 
inadequately screened (only one Pap test) with normal result; 3) unscreened; 4) having low-
grade abnormality; 5) having high-grade abnormality. It was estimated by cumulative 
incidence function considering competing events of death and total hysterectomy. We also 
estimated the hazard ratios of cervical cancer in relation to screening status at age 61-65 years 
across the five screening history groups using Cox regression models, adjusted for education 
and birth cohort. We further examined the difference in FIGO stage distribution of cervical 
cancer found at age 61-65 years by screening status at this age span. 
4.4.3 Study III 
This population-based case-control study included 4254 women diagnosed with primary 
invasive cervical cancer during 2002-2011. For each cancer case, 30 controls were randomly 
selected from the population who were free of cervical cancer up to the cancer diagnostic date 
of the corresponding cancer case, matched on birth cohort. Control subjects who had received 
total hysterectomy at the cancer diagnostic date of the corresponding cancer cases were further 
excluded. 
We assessed the cervical screening in two screening rounds prior to cancer diagnosis. The Pap 
test within six months prior to cancer diagnosis was disregarded, as cancer already existed 
when the test was performed. The length of previous two screening rounds varied by age at 
cancer diagnosis, which was six years for age 29-53, eight years for age 54-58, ten years for 
age 59-65, and screening at age 56-65 for those with cancer diagnosis above age 65. 
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We mainly used conditional logistic regression models to estimate: 1) relative risk of cervical 
cancer in women unscreened or inadequately screened compared to women screened in time 
in the past two screening rounds; 2) relative risk in women having abnormality in different 
patterns with biopsy status, compared to women screened in time with normal results only; 3) 
relative risk in women screened in time with normal results only, compared to women 
unscreened. 
4.4.4 Study IV 
This population-based cohort study included girls born between 1990 and 2003, and resident 
in Sweden between May 2007 and December 2014. Girls dead or emigrated before being 
eligible for the vaccination delivery, or immigrated after becoming eligible for the delivery, or 
vaccinated before being eligible were excluded. The cohort finally comprised 689,676 girls. 
They entered the cohort since being eligible for one delivery, and were followed until being 
vaccinated, emigration, death, or end of 2014. One can contribute to multiple delivery modes 
if eligible, before being HPV vaccinated. The eligibility for delivery modes by birth cohort or 
age was illustrated in Figure 5. Girls’ biological or foster parents were linked, and the parental 
country of birth (COB), level of education and disposable income in the year before the girl 
was eligible, was categorised. 
 
a. According to typical implementation 
Figure 5: eligibility of girls for different vaccination delivery by calendar year, based on birth cohort 
We plotted cumulative incidence curves of being vaccinated with the first dose (i.e. cumulative 
uptake) by parental COB, education and family income, as well as vaccination delivery mode. 
We then performed Cox regression models for each delivery mode to estimate hazard ratios of 
being vaccinated in relation to the three parental characteristics. 
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5 MAIN FINDINGS AND DISCUSSION 
5.1 SUCCESS AND WEAKNESSES OF CERVICAL SCREENING PROGRAMME 
5.1.1 Routine participation associated with significantly reduced risk 
In the previous case-control audit based on cervical cancer cases in 1999-2001, it was found 
that non-participation to cervical screening in the most recent screening round was associated 
with a higher incidence of cervical cancer (5). It was direct empirical evidence demonstrating 
a strong cervical cancer-preventive effect from screening. In the present case-control audit 
based on cervical cancer cases in 2002-2011, we examined the impact of previous two 
screening rounds, and found that being unscreened in the previous two screening rounds was 
associated with higher risk of cervical cancer (OR=4.1, 95%CI=3.8-4.5) than the risk 
associated with being unscreened for only the most recent round (OR=2.4, 95%CI=2.2-2.7). 
Moreover, we found that being unscreened in the previous screening round and screened in the 
most recent round was still associated with a statistically significant elevated risk compared to 
women screened in both of the screening rounds (OR=1.6, 95%CI=1.5-1.8) (Figure 6).  
Figure 6: odds ratios of cervical cancer of women with different screening status in the past two screening rounds, 
compared to women screened in both rounds (crude odds ratio in grey, adjusted odds ratio in purple) 
It suggests that a screening test may have a longer-term benefit, and the loss from missing one 
scheduled screening may not be completely compensated by the screening test in the next 
round. It may be due to the imperfect sensitivity of cytological test, thus repeat tests provide 
higher accuracy for disease-free status, and increase the chance to detect abnormalities. This 
emphasises the importance of routine participation to the screening. 
5.1.2 Being screened after abnormality associated with reduced risk 
The previous audit reported the benefit of taking biopsy shortly after an abnormality. In the 
present audit, we further evaluated the role of subsequent screening, and found that being 
screened in the most recent round in women having abnormality in the previous round was 
associated with statistically significantly reduced risk, no matter the initial abnormality was 
low-grade or high-grade, any biopsy was followed or not (Table 3). This finding confirmed the 
importance of keeping screening following an abnormality. 
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Table 3: odds ratios of cervical cancer (all types and stages) in women screened and unscreened in the recent 
screening round following abnormal result in the previous round, by type of abnormality and biopsy status 











Low-grade, biopsied - screened 23 649 Ref. Ref. 
Low-grade, biopsied - unscreened 14 70 5.7 (2.8-11.6) 5.9 (2.8-12.4) 
Low-grade, unbiopsied - screened 39 465 2.3 (1.4-3.9) Ref. 
Low-grade, unbiopsied - unscreened 27 105 7.5 (4.1-13.7) 3.3 (1.9-5.7) 
High-grade, biopsied - screened 77 649 3.4 (2.1-5.4) Ref. 
High-grade, biopsied - unscreened 21 76 7.7 (4.0-14.6) 2.1 (1.2-3.8) 
High-grade, unbiopsied - screened 18 158 3.1 (1.6-5.9) Ref. 
High-grade, unbiopsied - unscreened 22 32 19.3 (9.5-39.3) 7.1 (3.1-16.3) 
a. Left hand side of hyphen represents the previous screening round, and right hand side represents the most recent screening 
round  
b. Unconditional logistic regression, adjusted for age group and education 
5.1.3 Having abnormality associated with universally increased risk 
Nevertheless, we found that having an abnormality in any of the two previous screening rounds 
was always associated with an increased risk of cervical cancer. Even if the abnormality was 
found in the previous screening round and the screening in the most recent round showed 
normal, the risk was four times higher than women screened in time with normal results only 
(OR=4.0, 95%CI=3.2-5.1). It is understandable that having abnormality naturally yields 
increased risk, and the risk may not be completely eliminated by clinical management and 
treatment presumably due to potential immune susceptibility for recurrent disease. But since 
the primary aim of cervical screening is to prevent cancer by treating abnormalities, one need 
to consider to what extent the risk increase following abnormalities is acceptable, and whether 
the excess risk can be minimised by improving the management. At least the results highlighted 
that the close surveillance following an abnormality may warrant continuation for a certain 
period of time even if a normal result has been found.  
5.1.4 Lower effectiveness for preventing adenocarcinoma due to lower 
“protection” from normal test results and higher risk following 
abnormalities 
Studies constantly found that cervical screening using cytology was less beneficial in 
preventing adenocarcinoma of the cervix (56,59,61), which was also seen in our present audit. 
We found that 74% of cervical adenocarcinoma cases had participated in screening in the past 
two screening rounds, which was much higher than squamous cell carcinoma cases (53%). 
Furthermore, we found that, being screened with normal results in the past two screening 
rounds was associated with 89% risk reduction for squamous cell carcinoma (OR=0.11, 
95%CI=0.10-0.13) but only 60% for adenocarcinoma (OR=0.40, 95%CI=0.32-0.52) compared 
to women unscreened. The odds ratios in relation to having abnormalities in the past two 
screening rounds compared to women unscreened was much higher for adenocarcinoma than 





  27 
Table 4: odds ratios of cervical cancer among women having abnormalities compared to women unscreened in the 
past two screening rounds, by stage and histological type 
Screening historya Squamous cell carcinoma Adenocarcinoma 









All stages (age 29+)       
Unscreened – Unscreened 1368 22099 Ref. 207 5103 Ref. 
Abnormal – Normal 52 1139 0.5 (0.4- 0.7) 27 354 1.6 (1.1- 2.5) 
Abnormal – Unscreened 62 206 3.5 (2.6- 4.7) 17 57 6.2 (3.5-11.1) 
Nornal/Unscreened – Abnormal 272 1199 2.5 (2.1- 2.9) 74 317 4.9 (3.6- 6.7) 
Abnormal – Abnormal 45 226 2.2 (1.6- 3.1) 23 68 7.2 (4.4-12.0) 
a. Left hand side of hyphen represents the previous screening round, and right hand side represents the most recent 
screening round 
b. adjusted for education and age group 
Besides confirming the inferior preventive effect of screening for adenocarcinoma, our study 
further explained the cause of the inferior preventive effect, which were both lower “protection” 
from normal results and suboptimal effectiveness of managing abnormalities. The former was 
speculated to be associated with insufficient sampling of endocervical cells in Pap test. But the 
likelihood might not be high, because our previous analysis found that under the circumstance 
of 90% presence of endocervical cells over all Pap tests in Sweden (160), absence of 
endocervical cell in screening was not associated with increased risk of cervical cancer in the 
subsequent screening interval (OR=1.03, 95%CI=0.84-1.26). Therefore, it might be more 
likely to be due to the difficulty in sampling lesions locating up into deep cervical canal (161), 
or the lesion occur beneath the transformation zone and may thus be covered by normal or 
metaplasitic epithelium (162). It might also be likely that the pre-invasive lesions for 
adenocarcinoma progress rapidly so that the regular three-year interval is too long to detect it. 
The suboptimal effectiveness of managing abnormalities may arise from insufficient 
understanding of the risk following certain abnormalities, so that the following management is 
not optimally addressed.  
5.2 ATYPICAL GLANDULAR CELLS IN SCREENING ASSOCIATED HIGH RISK 
OF CERVICAL CANCER, ESPECIALLY ADENOCARCINOMA 
One of the suboptimal management following abnormality mentioned above may manifest in 
an uncommon cytological finding “atypical glandular cells” (AGC).  
In study I, we found that women having AGC in cervical screening were associated with a 
remarkably increased risk of invasive cervical cancer in the subsequent six years, and the 
increased risk lasted for 15 years compared to women with normal screening results (Table 3 
in paper I). The incidence from 0.5 to 6.5 years was higher than HSIL. Adenocarcinoma was 
the dominant histological type of cervical cancer following AGC (Figure 7). 
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Figure 7: Crude incidence rates of incident cervical cancers at follow-up of AGC, HSIL, and LSIL, by 
histopathology of cancer. To avoid sparse and fluctuating data, right end point of follow-up time, denotes incidence 
at 10.5-15.5 years (Fig 3 in paper I) 
We considered that although cancer cases found in the first six months following AGC were 
presented separately as prevalent cancer, there might still be residual prevalent cancer being 
detected later due to no immediate histology assessment, potentially resulting in a higher 
incidence than HSIL. We therefore did further analyses taking histology assessment in to 
consideration, and found that only 54% of women having AGC were followed by histology 
within six months, which was much lower than the 86% following HSIL. Within women being 
assessed with histology, 2.8% of women with AGC were found to have prevalent cancer, which 
was close to 3.2% for HSIL, and the cancer incidence in the subsequent six years following 
AGC was still significantly higher than that following HSIL (Table 5). 
Table 5: Prevalent and incident cervical cancer (all histopathologies) associated with AGC, HSIL, and LSIL among 
women with histology assessment within six months, by follow-up time (Table 6 in paper I) 
 
The results suggest that, AGC may be associated with the development of cervical 
adenocarcinoma, hence it spontaneously possesses a considerable risk of developing cervical 
adenocarcinoma, and the risk was not suppressed by following management to the similar to 
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that as for HSIL for squamous cell carcinoma. The lower proportion of follow-up with 
histology indicated that the potential high risk may not have been well recognised, and the 
higher risk than HSIL after being followed with histology implied that the current management 
approaches, established mainly from empirical evidence for addressing squamous cell 
abnormalities, may not be similarly effective for addressing glandular ones. The glandular 
lesions may hide up in the cervical canal and are therefore not visible under colposcopy, and 
the blind biopsy, if performed, may barely access the lesion. Moreover, the precursor lesion, 
adenocarcinoma in situ (AIS), may progression to invasive adenocarcinoma in shorter time, 
and thus the regular follow-up interval may not be short enough to catch AIS. Furthermore, 
even if AIS was found, the treatment for AIS does not appear as effective as the treatment for 
CIN3 in terms of reducing subsequent invasive cancer (163–165). That may be partially 
manifested by our finding that the cancer risk was higher among younger ages when AGC was 
found, since the treatment may be less aggressive considering patients’ demand of childbearing. 
Although our findings were based on cytological screening, it could be of great significance in 
upcoming HPV primary screening, as cytology will be performed as one of the reliable triages, 
and others have found that HPV-positive AGC had much higher risk of cervical cancer than 
HPV-negative ones in the subsequent five years (166). Therefore, AGC found in cytology 
triage under HPV primary screening warrants particular attention. Clinicians should be made 
aware of these patients, and more aggressive management strategy may be considered, such as 
biopsy into upper endocervix, and closer surveillance afterwards. 
Although this study showed a clear association between AGC and cervical adenocarcinoma, 
anticipating a great improvement of prevention against adenocarcinoma by optimising 
management of AGC may not be practical, as we found in the above audit data that only around 
10% of cervical adenocarcinoma cases had history of AGC in the past two screening rounds 
(Table 6). Other efforts still need to be made. 






5.3 CERVICAL CANCER RISK AND THE EFFECTIVENESS OF SCREENING 
AFTER AGE 60 VARIED LARGELY BY SCREENING HISTORY AT AGE 51-
60 YEARS 
Giving the unexpected high incidence of cervical cancer among women aged 60 and above, we 
tried to investigate the underlying reasons, and explore whether performing additional 
screening after age 60 would ease the problem. 
Abnormality % among 
adenocarcinoma 
% among squamous 
cell carcinoma 
LSIL 7.2 13.3 
HSIL 4.1 9.5 
AGC 4.4 1.1 
AGC&LSIL 3.4 0.7 
AGC&HSIL 1.8 0.7 
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In study II, we first assessed the distribution of screening history among women aged 51-60 
over decades, and plotted the cervical cancer incidence rates at age 60-79 years. We found that 
along with the increase in proportion of women being adequately screened at age 51-60 years, 
there was a decrease of cervical cancer incidence rates after age 60 years (Figure 8). This 
finding supported the explanation given by an recent ecological study, which suggested that 
the observed high incidence of cervical cancer in older-aged women in Nordic countries may 
due to insufficient earlier-life screening background of the older birth cohorts, although that 
study was only able to assess age-specific cervical cancer incidence by birth cohorts (102).  
Figure 8: Distribution of screening status among women aged 51-60 years and incidence of invasive cervical 
cancer in women aged 60-79 years by calendar year 
 
To further justify this argument, we performed the individual-level cohort study, and found that 
women who were adequately screened with normal results at age 51-60 presented a relatively 
low cumulative incidence of cervical cancer, which was 1.6 per 1000 women, from age 61 to 
80 years. The cumulative incidence was much lower than among women unscreened, having 
low-grade or high-grade abnormalities in their 50s, which were 5.0, 9.7 and 15.3 per 1000 
women, respectively (Table 2 in paper II). This evidence further confirmed that cervical cancer 
incidence at older ages depended largely on screening history. 
In addition, we found that the impact of cervical screening after age 60 also varied by screening 
history (Figure 9). In women unscreened or having abnormalities in their 50s, being screened 
at age 61-65 years was associated with close to or more than 50% risk reduction up to age 80 
years (HR=0.42, 0.53 and 0.59 in women unscreened, having low-grade or high-grade 
abnormality in their 50s, respectively). However, in women screened with normal results in 
their 50s, no statistically significant risk reduction was found to be associated with further 
screening (HR=0.90, 95%CI=0.69-1.17), but only a down-staging effect. This finding 
suggested a potential wane of cancer preventive effect from cervical screening with age, and it 
was preliminarily supported by our supplementary finding that the screening at ages 56-60 was 
associated with statistically significant risk reduction up to age 80 in women previously 
screened with normal results (HR=0.69, 95%CI=0.55-0.86). The potential wane of effect was 
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expected by previous findings that the detection rate of cervical precursor lesions decreased 
over age (92), especially among women being screened in the past (167,168). The low detection 
rate may be caused by both rare development of the diseases due to less HPV exposure after 
reproductive ages, and low sensitivity of cytological test at older ages when the transformation 
zone moves up into cervical cannel following hormone changes.  
Figure 9: Cumulative incidence and 95% confidence intervals of cervical cancer among women screened and 
unscreened at age 61-65, by screening history at age 51-60, considering death and total hysterectomy as 
competing events. Red dotted line: unscreened at age 61-65; blue solid line: screened at age 61-65. Note that the 
scales of y-axis are different between the first and second row (Fig 3 in paper 2).  
 
The above two causes for low detection rate of precursor lesions hint that HPV primary 
screening may have better performance at older ages, since HPV negative testing results may 
mean longer “protection” given the lower probability of acquiring new infection than younger 
ages (88,89), and HPV-primary screening may detect more precursor lesions by closer follow-
up of HPV-positive cytology-negative women. We could speculate that performing HPV 
testing after age 60 in women screened with cytological normal results in their 50s may yield 
a further reduction of the residual subsequent risk. While it would also be of great interest to 
investigate whether the HPV test after age 60 is beneficial for those having been tested with 
repeat HPV-negative results in their 50s.  
Previous studies reported significant effect of cervical screening after age 60 years in 
preventing cervical cancer regardless of screening history (4,6,169). This justifies performing 
the screening in this age group when a large proportion of women turning 60 years of age were 
not adequately screened in their 50s. As time goes on, increasing number of women will be 
adequately screened, thus a cost-efficient screening program for older aged women may have 
to be based on an individualised strategy. 
 32 
Mortality is usually examined when evaluating effectiveness of screening. It was not included 
in this study because 1) cervical cancer-specific mortality was very rare at the studied age group 
as death from other reasons, which was not uncommon, was a strong competing event for 
cervical cancer death; 2) difference in overall mortality between screened and unscreened 
women may largely reflect the influence of life-style factors associated with screening 
attendance, thus was hardly attributed to screening alone.  
5.4 DELIVERY MODE OF HPV VACCINATION ASSOCIATED WITH 
DISPARITIES OF VACCINE UPTAKE 
In study IV, we found that the free-of-charge school-based vaccination yielded the highest 
overall uptake and lowest disparities in parental country of birth, education and family income, 
followed by the free-of-charge catch-up vaccination administrating outside of schools. The 
subsidised opportunistic vaccination showed the lowest uptake and strongest socioeconomic 
disparities (Figure 10). 
Figure 10: Cumulative uptake of HPV vaccine by maternal characteristics and vaccination policy (Figure 4 in 
paper IV) 
The experience from healthcare services shows that individuals with migration or lower 
socioeconomic background are usually hard to reach (125,127,128,170,171). This is 
particularly seen in the subsidised opportunistic HPV vaccination in this study, where girls with 
foreign-born, lower educated, or lower income parents were vaccinated to the lowest level. In 
catch-up vaccination, the co-payment for individuals was rescinded. Although many 
information channels, e.g. school or media commercial, invitation letter, etc., were organised 
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by each county (147), in counties administrating the vaccination outside of schools, the uptake 
was suboptimal and disparities were still pronounced despite an improvement from the 
subsidised vaccination. The achievement of school-based vaccination, however, suggests that 
school organisation, which offers convenient access, may play important role on improving 
uptake in all socioeconomic groups. One important limitation of this study was that assessment 
of the uptake in counties administrating catch-up vaccination in schools was hampered, because 
the two counties fulfilling the criteria were small in population and co-located, thus the scenario 
may be different from other counties. Even though, in our supplementary analysis, the two 
counties exhibited similar overall uptake of the vaccine as school-based vaccination, and the 
socioeconomic disparities were mostly close to the school-based vaccination (Table 7). On the 
basis of previous findings that school organisation achieved higher vaccination coverage in 
adolescence, our study further demonstrated that it could also assisted on attaining social 
equality in vaccine uptake. 
Table 7: adjusted hazard ratio of HPV vaccine associated with maternal characteristics, including catch-up 
vaccination administrated in schools 






Country of birth       
Sweden  Ref. Ref. Ref. 
Other countries  0.68 (0.65-0.71) 0.91 (0.84-0.99) 0.82 (0.81-0.83) 
Education level    
High  Ref. Ref. Ref. 
Medium  0.87 (0.85-0.90) 0.92 (0.88-0.97) 0.95 (0.94-0.96) 
Low  0.73 (0.69-0.77) 0.90 (0.83-0.98) 0.92 (0.91-0.94) 
Family income     
High  Ref. Ref. Ref. 
Medium  0.87 (0.84-0.90) 0.91 (0.86-0.96) 0.92 (0.91-0.94) 
Low  0.79 (0.76-0.82) 0.79 (0.74-0.84) 0.87 (0.85-0.88) 
Having migration or lower socioeconomic background was also found to be associated with 
lower participation to cervical screening (172,173). Although school administration was not 
applicable for the delivery of cervical screening, the essence of providing convenient access of 
the service may be referred for diminishing socioeconomic inequality of screening participation, 
for instance offering self-sampling screening test for non-attendants.  
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6 METHODOLOGICAL CONSIDERTATIONS 
6.1 STUDIY DESIGN 
In this thesis work, two main observational study designs, cohort and case-control design, were 
utilised. Cohort study is generally considered to be at high rank of evidence hierarchy among 
observational study designs (174). However, the case-control design conducted in this thesis 
should provide similar validity on measuring relative risk, as in this instance if first using 
register data to collect the exposure avoided the exposure status being influenced by the 
occurrence of the outcome, from which the conventional retrospective case-control design 
usually suffers. Second, it was performed as a nested case-control study using density-based 
sampling for control selection, which meant that the control subjects were randomly selected 
from the population which had the same key characteristics as the corresponding case, and at 
risk of cervical cancer at the time of the diagnosis of the case. This was achieved through 
matching on birth cohort, and allowing a case to also act as the control for other cases before 
diagnosis. It ensured that the controls were from same the population that gave rise to the cases. 
Under these conditions, the odds ratios estimated in case-control study can be considered 
equivalent to the incidence rate ratios estimated in a cohort study.  
Theoretically, these four studies could have all been performed with an alternative design. 
However, there are particular strengths of each design that suitable for specific research 
questions. The absolute risks are of particular interest in study I, II and IV (absolute risk of 
cervical cancer after AGC, after age 60, and absolute uptake of HPV vaccine, respectively), 
whereupon cohort design offering direct and flexible measures of the absolute risk is more 
appropriate. Particularly in study I, as AGC is a rare exposure, cohort design which makes use 
of all cytological diagnosis of AGC in the database is more sufficient. Yet in study III, the 
absolute risk of cervical cancer by screening status is not a primary interest, thus case-control 
design involving less subjects becomes more efficient in estimating the relative risk. Moreover, 
by restricting the cancer cases to a defined time period, the collection of information from 
medical charts and verification of histological type of the cancer cases becomes feasible and 
convenient. 
6.2 REGRESSION MODEL 
Within each study design, statistical models were also carefully selected according to specific 
research questions of the four studies. In cohort design, Poisson and Cox regressions can both 
estimate the relative risk associated with the exposure. Poisson regression allows flexible 
estimations of relative risk on the underlying time scale of follow-up, whereas Cox regression 
assumes a constant effect of the exposure over the entire follow-up, so called proportional 
hazard assumption. In study I where the long-term risk following AGC was examined, the risk 
in relation to women with normal screening results were substantially heterogeneous over the 
15 years, and the heterogeneity over time was of interest as a research question. Hence it is 
much easier to model with Poisson regression. On the other hand in study II and IV, the “effect” 
of screening after age 60 years for cervical cancer development, and socioeconomic status for 
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HPV vaccine uptake, was quite constant over the follow-up period, which was approved by the 
tests of proportional hazard assumption, thus Cox regression model provides plain and 
straightforward measurement of the association.  
Logistic regression model is generally used for case-control studies. In study III, as the case 
and control subjects were matched on birth cohort, using conditional logistic regression which 
models the probability stratifying by the matching clusters, is crucial as it removes the bias that 
were potentially introduced by matching if analysed via regular approach. However, in specific 
sub-analyses when the exposure was extremely rare, for instance when assessing the effect of 
screening following different grade of abnormalities as well as biopsy status, using conditional 
logistic regression ended up with poor precision. We therefore used ordinary logistic regression 
model adjusting for age, which captured the key influence from birth cohort in the only ten-
year study period. This model also largely reduced the impact of potential bias introduced by 
matching. 
6.3 CONFOUNDING  
Observational studies usually suffer from confounders, which bridge a synthetic association 
between examined exposure and outcome. Existence of confounding factors distorts the 
magnitude of the true association between exposure and outcome, and disables the causal 
interpretation of the association, because it hinders the exchangeability between the exposed 
and unexposed group hence the two groups are not considered homogenous besides the 
exposure factor. By adjusting confounding factors in analyses, the association is amended, and 
the causality is defended as conditional exchangeability is yielded. 
In this thesis, examining the effect of cervical screening on cervical cancer risk is prone to 
suffer from several potential confounding factors: a) Birth cohort. The older birth cohorts 
generally had poorer screening profile, and may have lower baseline risk of cervical cancer due 
to different sexual behaviour pattern compared to younger birth cohorts. Therefore, the effect 
of screening may be diluted if not adjusting for it. b) Age. Women at different ages have 
different levels of screening participation, and age is an important risk factor for cervical cancer. 
c) Education. Higher education is generally associated with higher screening participation, and 
may also directly relate to lower cancer risk due to lifestyle or environmental conditions. Hence 
the effect of screening may be amplified. d) Behaviour factors, such as age at sexual debut, 
number of partners, parity and smoking, are well-established risk factors of cervical cancer. 
They may also be positively or negatively associated with screening participation depending 
on individuals’ perceived risk of developing cervical cancer as well as health consciousness. e) 
Health consciousness. People who are more health-conscious usually are more likely to adhere 
to screening, health consciousness may also have influence on cervical cancer development 
through lifestyle or psychological factors. 
6.3.1 Addressing confounding from birth cohort and age 
Birth cohort has close relationship with age and calendar period, so controlling for birth cohort 
may capture confounding effect from different aspects in different studies. In study II where 
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age at screening was defined, adjusting for birth cohort also controlled for potential 
confounding from calendar period. The results that the magnitude of hazard ratios was slightly 
changed after adjusting for birth cohort supported the existence of the confounding effect. In 
study III, cases and controls were matched by birth cohort, which was an efficient approach to 
control for confounders in case-control design. Since the time period for cancer cases was 
defined as only ten years, matching on birth cohort captured more of confounding from age 
than the calendar period. When matching, the magnitude of confounding effect of the matching 
factor was not possible to estimate. 
Confounding from age was also considered in study I when comparing the risk of cervical 
cancer following AGC to women screened with normal results, since both the prevalence of 
AGC and risk of cervical cancer were highly related to age. We adjusted for attained age when 
assessing the relative risk of cancer following AGC, which makes sure that the risk ratio at 
each time point during follow-up reflects the comparison with women having normal screening 
results at the same age. 
6.3.2 Addressing and discussing confounding from education, behaviour 
and health consciousness 
Previous studies evaluating effectiveness of cervical screening rarely controlled for social-
psychology-behaviour factors, thus were challenged that the association could be confounded 
by self-selection, that women participating to screening are a selected group of certain 
characteristics which may have low underlying risk of cervical cancer even without screening. 
Those characteristics may include education, behaviours, and health consciousness, which are 
intimately associated with each other. 
Education was adjusted in study II and III. We found in study II that the estimates of hazard 
ratio of developing cervical cancer in relation to screening status at age 61-65 years was barely 
changed when adjusted for education only. Similarly in study III, adjusting for education did 
not alter the odds ratio. We therefore speculate that education may be associated with screening 
participation, but has a weakly direct association with cervical cancer development.  
However, great majority of cervical cancer related behaviour factors were impossible to be 
addressed in this thesis, since they were not recorded in register data. The only factor with 
relatively complete register data over time was parity, for which the number of children of each 
woman was recorded in Multi-Generation Register. High parity is usually related to lower 
screening participation because screening was usually not performed among pregnant women. 
And parity is an established risk factor for cervical cancer which may be due to hormone related 
cervical ectopy and cervical trauma during vaginal delivery (175,176). However, we found in 
study II and III that adjusting for parity did not alter the results. To assess how unmeasured 
sexual behaviour factors may confound our results, we extracted data from a survey conducted 
in 2007 in Sweden covering young women under age 30 years (132), and found that in women 
aged 25-30 years, age at sexual debut and condom use with temporary partners was not 
associated with screening participation, while women having more than one partners in the past 
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year participated slightly less to cervical screening compared to women having no or one 
partner (Table 8). This suggests that, if the association was similar among other ages, the 
reported association between screening participation and cervical cancer development in study 
II and III might be slightly overestimated, but the influence was minimal. 
Table 8: screening participation by sexual behaviour factors in young women, from survey 2007 





Age at sexual debut <15 (22%) 89.3 0.13 
 >=15 (78%) 91.2 
No. partners past year >1 (24%) 86.7 <0.01 
 0-1 (76%) 91.7 
Condom use with temp. partners Rarely or never (21%) 89.2 0.13 
 Use (79%) 90.9 
Health consciousness was also impossible to measure in our register-based study. However, 
since it is closely associated with socioeconomic status (177,178), the adjustment for education 
may have reduced its influence. In addition, we consider that the impact of health consciousness 
on the association between screening and cervical cancer risk may be related to the coverage 
of screening, that the confounding effect could be stronger if very few women in the population 
went to screening. Thus when evaluating the effectiveness of screening after age 60 in study II, 
since only a part of counties organised or encouraged screening above age 60 years, the 
coverage of screening varied. We performed sensitivity analysis restricting to counties that had 
more than 40% women screened at ages 61-65, to ensure that counties that had very few women 
being screened did not dominated the result that otherwise might be strongly health-conscious. 
In study III, as the coverage of screening was above 70% in the entire population (160), we 
consider that the confounding effect from health consciousness may not overwhelm the true 
effect of screening, especially after adjusting for education. 
6.4 BIAS 
Generally, bias is a factor that causes distortion of the association between studied exposure 
and outcome, thus confounding and misclassification can be considered as sources of bias. In 
conventional understanding, bias usually comes from incorrect selection of study population, 
i.e. selection bias, and incorrect measurements of exposure and outcome factors, i.e. 
information bias. The four studies in this thesis generally suffered little from selection and 
information bias, because the study population were the entire population in Sweden, and the 
information of exposures and outcomes were derived from registers instead of reported by 
individuals relying on recall.  
One potential selection bias could exist in study II, since only women living in the counties that 
started cervical screening register before they turned age 51 years were included in the study. 
It was mainly due to county-based administration. However, there would be bias if the 
characteristics of population were systematically different between counties that started the 
record of screening in early and later years. To evaluate the difference between women 
included and excluded due to availability of screening record, we compared the level of 
education between the two groups, and found that women included in the study were slightly 
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higher educated, yet the difference was minimal (Table B in S2 text of study 2). Furthermore, 
since the inclusion due to screening record availability also results in different proportion of 
inclusion by birth cohorts, i.e. women born in later years had larger proportion of having 
screening record available since age 51 years (Figure 11), we performed sensitivity analysis 
restricting to younger birth cohorts, and found the results almost unaltered (Table E in S2 text 
of study 2). We thus believe that the selection bias in study II was not a major concern. 
Figure 11: Number of women having (grey bar) or not having (white bar) cervical screening records from age 51 
by year of birth, and amount of person-years of follow-up contributed in women having screening records from 
age 51 by age category and calendar year (lines) 
Table 9: Characteristics of population in counties included and excluded in study IV due to anonymous vaccination 
issue 
 16 counties 
in study 
5 counties having 30% 
anonymous vaccination 
Mean age 42.0 42.8 
Country of birth   
Sweden 84.0% 86.3% 
Other countries 15.9% 13.6% 
Missing 0.1% 0.1% 
Education in ages 35-65   
low 12.9% 13.4% 
Medium 45.1% 47.2% 
high 41.1% 38.7% 
Missing 0.9% 0.7% 
Family income in ages 35-65   
low 33.8% 34.6% 
Medium 32.8% 34.4% 
high 33.0% 30.7% 
Missing 0.4% 0.4 
Another potential selection bias could exist in study IV when five out of 21 counties that had 
more than 30% anonymous vaccination in SVEVAC was excluded from the analysis. Four of 
the five counties are small to middle size in population, and one county is the second large 
county in Sweden. We compared the population characteristics of the five counties to the other 
16 counties, and found that there were slightly more Swedish-born, and slightly lower 
education and income in the five counties (Table 9). However, the differences were too small 
to justify an obvious selection bias. 
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6.5 MISCLASSIFICATION 
The only clear misclassification in this thesis work was the vaccination status in study IV. Due 
to anonymous vaccination in the register SVEVAC, girls vaccinated without identity were 
classified as unvaccinated. It was hardly known whether the misclassification was differential 
or non-differential in relation to the studied social disparity factors, because the characteristics 
of the girls in terms of socioeconomic status cannot be assessed without identity of the girls. 
To minimise the influence of misclassification, we excluded the counties that had more than 
30% anonymous vaccination, and performed sensitivity analysis restricting to counties having 
less than 15% anonymous vaccination, in which the results of association between parental 
socioeconomic factors and girls’ HPV vaccine uptake across delivery modes of the vaccination 
were not changed. This suggested that the misclassification may not have considerable 
influence on the results. 
Unknown misclassification associated with registers may exist, as register data is by no means 
100% correct. Yet we believe that the potential unknown misclassifications were most likely 
non-differential between the examined exposures and outcomes, thus may have little impact 
on the results other than slightly diluted the examined associations.  
6.6 GENERALISABILITY 
Whether the results of the four studies can be generalised to other settings deserve a discussion. 
The effectiveness of screening found in our studies may not directly translate to other countries, 
because firstly, the sensitivity of cytological test which relies on subjective judgement, is close 
to 80% in Sweden, yet varied between 30% and 90% across settings (27); and secondly, the 
management following abnormalities also differs. It may lead to various magnitudes of 
effectiveness of cervical screening, although the beneficial effect may hardly be overturned. 
Policy making for screening practice referencing our results should therefore be cautious on 
potential inaccurate prediction of cost-benefit if the sensitivity of Pap test or management 
following abnormalities are different from Sweden.  
The results of socioeconomic disparities in HPV vaccine uptake by delivery mode of the 
vaccination may to a large extent generalisable to wider settings, as we considered the 
comparability with other countries or cultures when choosing the indicators for migration and 
socioeconomic background. However, marginal differences may remain, because there could 
still be residual discrepancies in sociological significance for the same indicators in other 
settings. For instance, the foreign-born groups in North America or Asia could have different 
composition from those in Sweden in terms of cultural background, and the immigrants in 
different countries may develop different attitudes. Besides, as the overall income in Sweden 
is relatively high over countries worldwide, the individuals’ sensitivity to the price or price 
change of the HPV vaccine could be different from that in low-income countries, and the social 
stratification by income may be more likely to imply differences in other socio-psychological 
aspects than the amount of income itself. Particularly when facing a newly introduced vaccine, 
the discrepant degrees of trust to authorities as well as impact of anti-vaccine movement may 
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all affect the attitude and behaviour in different socioeconomic groups across different 
countries. Hence, similar evaluations from different settings will be of particular value. 
6.7 CHALLENGE IN EVALUATING THE EFFECTIVENESS OF CERVICAL 
SCREENING 
Cervical screening test can both detect the existing cervical cancer and prevent cancer that 
would develop in the future. Therefore, a screening test could lead to an increase of cervical 
cancer incidence within a short period of time, and a decrease of incidence in the long run. 
Figure 12 illustrates a likely pattern of the differences in observed cervical cancer incidence 
between screened and unscreened women at different time period following a screening test 
(the black dot). During the initial six months, due to the diagnosis of existing cancer (or called 
prevalent cancer) detected by screening, women being screened were found more cancer cases 
than those unscreened. Then in the following time period (the blue line), the unscreened group 
presents with a higher incidence than the screened group, partially because the cancer cases 
that are diagnosed by the screening test during the initial six months, usually before symptom 
onset, in the screened group are diagnosed in this period in the unscreened group. Thus it can 
be considered as a “washout period” for the cancer cases having onset in the initial six months. 
Thereafter, a lower incidence in the screened group may still be observed during certain time 
period, which should be due to the preventive effect of the initial screening test. After this 
period, the effect of this screening test wanes thus the screened and unscreened group will 
present similar incidence. 
Figure 12: Pattern of cancer detection following a screening test (arrows represent relatively higher or lower 
detection rate of cervical cancer comparing screened and unscreened group) 
The challenging point of evaluating the effectiveness of cervical screening is how to accurately 
examine the preventive effect, because the effect observed during the blue line involves both 
the “washout” effect caused by early detection of unpreventable cancer cases, and the true 
preventive effect by detecting and removing precursor lesions. For instance, stage IA cancer 
detected by screening within the initial six months may have been diagnosed in one to two 
years if the screening were not performed, thus the incidence difference observed between 
screened and unscreened group in the following one to two years is not a preventive effect; 
Whereas, CIN3 or adenocarcinoma in situ detected at the screening would have progressed to 
invasive cervical cancer in one to two years if the screening were not performed, in this case 
the incidence difference observed in one to two years represents a true preventive effect.  
Unscreened 
Unknown length 6 months Unknown length 
Screened 
Unknown length 6 months Unknown length 
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In study II, since the primary research question was whether the screening test after age 60 can 
prevent cervical cancer, we performed a cohort analysis evaluating the cumulative incidence 
of cervical cancer, and allowed the screen-detected prevalent cancer cases to be the outcome 
of the screened group. The beauty of this approach is that one does not need to for the timeline 
to distinguish the cancer cases that can and cannot be prevented by the screening test, which is 
the key challenge described above. As long as there is a difference in cumulative incidence that 
can be observed by the end of follow-up, there must be preventive effect occurring during 
follow-up. And it presents an intuitive short-term and long-term impact of one single screening 
test. 
However in study III, where the main aim was to accurately quantify the pure preventive effect 
of screening, it is important to distinguish which screening tests can serve to prevent a cancer 
case. Obviously, in the case-control frame, the screening test within six months prior to cancer 
diagnosis should be disregarded, which was done in the current analysis, as well as the first 
audit (5) and the audit in UK (4). However, in addition, screening tests during a time period 
preceding the six months may also need to be disregarded, corresponding to the “washout” 
period in the above schema with prospective view. Figure 13 is the corresponding schema with 
retrospective view in case-control design frame. The scenario during the blue line time here is 
as tricky as above, the difference in odds of having screening test during the blue line between 
the cases and controls mixed “washout” effect and true preventive effect. The “washout” effect 
is originated because for the case subjects the cancer may already have developed at time of 
the blue line, so if a Pap test were performed, the cancer would have been diagnosed at that 
time point. Hence a cancer case diagnosed at time X may be very unlikely to have a Pap test 
during the blue line time. And the true preventive effect comes from the likely situation that a 
CIN3 or adenocarcinoma in situ is detected in a control subject during the blue line time - thus 
the cancer that would have appeared at time X is prevented. The crucial handling to examine 
the true preventive effect is to find a cut-off time point at the blue line that can maximally 
distinguish the “washout” and preventive effect. The “washout” period echoes the concept of 
occult invasive phase of cervical cancer, which is the time between the onset of cancer and the 
symptom, with the screening for early detection of the cancer usually taking place during this 
time. However, the length of occult invasive phase of cervical cancer does not directly translate 
to the length of the washout period in our study, because for a screen-detected cancer the length 
of the washout period is the length of the true occult invasive phase minus the time that gained 
by the screening. The length of occult invasive phase of cervical cancer remained unclear. One 
study reported from modelling that up to two years all cervical cancer cases diagnosed at occult 
invasive stage progress to clinical stage (179). Consider that 29% of cancer cases were screen-
detected in our study then the average length of the washout period might be estimated to 
approximately one to one and a half year. It is also reported that very few cervical cancer were 
diagnosed within one to two year after detection of CIN3 (180). Therefore we performed the 
sensitivity analysis in study III disregarding Pap test within 12 months and 18 months prior to 
cancer diagnosis, and found that the point estimates of odds ratios were slightly reduced, but 
the confidence intervals were mostly overlapped with the original analysis, and the significance 
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compare to women screened in time did not change  (Table 10). The conclusions were therefore 
not violated.  
Figure 13: Pattern of screening history prior to cancer diagnosis in case and the corresponding control (arrows 
represent relatively higher or lower probability of having a screening test comparing case and control) 
Table 10: adjusted odds ratiosa of cervical cancer in relation to screening status in the past two screening rounds, 
by number of months prior to cancer diagnosis for disregarding non-preventive Pap test  
 6 months  12 months 18 months 
Unscreened  – Unscreened 4.14 (3.79-4.52) 3.91 (3.58-4.27) 3.56 (3.27-3.88) 
Screened – Unscreened 2.40 (2.18-2.65) 2.03 (1.84-2.24) 1.63 (1.47-1.81) 
Unscreened – Screened 1.63 (1.46-1.81) 1.54 (1.38-1.71) 1.49 (1.34-1.66) 
Screened – Screened Ref. Ref. Ref. 
a. adjusted for education and age group 
More research is needed to find out the optimal cut-off to distinguish the washout and 




6 months Two screening rounds 
Case 
Unknown length 6 months Two screening rounds 
Control 
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7 CONCLUSIONS 
Participating to cervical screening following a recommended interval was associated with a 
substantially reduced risk of invasive cervical cancer. Missing scheduled screening yielded an 
increased risk of cervical cancer in both the short and longer term, and the excess risk was not 
completely eliminated even if participated in the next round of screening.  
Having an abnormality in cervical screening was associated with an increased risk of cervical 
cancer compared to having normal results only. Being screened in the subsequent round 
following abnormality yielded a clear reduction of the elevated risk. However, a residual excess 
risk remained even if the screening in the subsequent round reported normal. 
The inferior preventive effect of cervical screening against adenocarcinoma compared to 
squamous cell carcinoma of the cervix was due to both lower assurance from repeat normal 
test results, and higher risk following abnormalities. 
Atypical glandular cells found in cervical screening implies increased risk of incident cervical 
cancer in the subsequent 15 years, especially for adenocarcinoma of the cervix. The incidence 
was higher than following high-grade squamous intraepithelial lesions in the subsequent 6 
years, even the initial histology assessment was performed. 
Cervical screening at ages 61-65 was associated with substantially reduced risk of cervical 
cancer up to age 80 in women being unscreened or having abnormalities in their 50s. Yet in 
women screened with normal result(s) in their 50s, the subsequent risk of invasive cervical 
cancer was not sizable, and the screening after age 60 was not associated with statistically 
significant risk reduction. 
The free-of-charge school-based delivery of HPV vaccination achieved the highest vaccine 
uptake with lowest social disparity, compared to the delivery modes requiring co-payment 
and/or administrating outside of schools. 
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8 IMPLICATIONS AND FUTURE DIRECTIONS 
Through optimised study design, we reinforced the evidence of the effectiveness of cervical 
screening, and justified the importance of routine participation to screening. We also identified 
suboptimal aspects in cervical screening programme, which may guide further efforts in 
research and practice for improvement. As examples of such further research, we utilised the 
rich register database to address two specific clinical questions of wide concern, regarding risk 
of glandular abnormalities in relation to unsatisfactory cancer prevention for adenocarcinoma, 
and effectiveness of screening for older aged women. The findings provided real-life evidence 
for potential amendments in practice to improve the screening performance. Furthermore, we 
verified the role of delivery mode in reducing disparities of HPV vaccine uptake, which 
informed the exertion of promoting equal acquisition of cervical cancer prevention. 
Research and practice following present findings may facilitate the elimination of cervical 
cancer. Despite an up to 70-80% coverage of cervical screening, more than 50% of cervical 
cancer cases arose from women being not screened or not routinely screened. Reaching the rest 
20-30% and encouraging routine participation will be a long-term effort. A randomised trial 
found that offering reminder, especially phone reminder to the short-term non-attendants can 
increase attendance (181), and the ongoing trial of offering self-sampling HPV test for the long-
term non-attendants appears promising. Self-sampling provides easy access, thus may reduce 
the socioeconomic disparities of the screening attendance given the experience from vaccine 
uptake, while lower socioeconomic status was shown to be significantly associated with lower 
screening participation (173,182–184). 
Optimising clinical management for abnormalities found in screening could further enhance 
the preventive effect of screening. Take the studied AGC as example, since a higher cervical 
cancer incidence was seen even after histology assessment, the natural history of glandular 
dysplasia of the cervix need to be comprehensively examined, and if adenocarcinoma in situ 
(AIS) is the downstream lesion on the progression pathway, the optimal follow-up interval after 
AGC needs to be investigated in order to detect AIS. Furthermore, since the effectiveness of 
treatment for AIS is less satisfactory compared to the treatment for squamous cell carcinoma 
in situ (163–165), research about improved treatment or follow-up strategy after treatment of 
AIS is crucial. Similar research would also meet the needs of reducing increased risk following 
other abnormalities, especially focusing on the management after treatment, and the sufficient 
number of normal test results after abnormality or treatment to safely return women back to 
regular screening interval. The optimal management strategy might be different for different 
abnormalities, which warrants specific research focus, and particular attention in practice. 
To improve prevention against adenocarcinoma, optimising management for AGC and AIS is 
not enough, as more than 30% cervical adenocarcinoma cases had only normal results in the 
recent screening round. Questions remain about whether the abnormality has been missed; if 
not, what is the reason for the rapid development, whether there is any indicator for rapid 
development such as infection of specific type of HPV, or immune characteristics; what is the 
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rationale of better prevention of HPV primary testing which was found in randomised trial 
(185), and whether it relies on specific triage technique or interval strategy for women with 
HPV positive results. 
For concrete evidence of discontinuing screening at older ages, future studies can consider 
addressing a systematic evaluation of effectiveness of cervical screening over ages 45-70 years, 
including not only quantification of the preventive and down-staging effect against invasive 
cervical cancer, but also assessment of detection rate of precursor lesions, in relation to 
previous screening results. Moreover, although the effectiveness of cervical screening after age 
60 was not found to be significant in women screened with normal results in their 50s according 
to our study, factors for residual risk of developing cervical cancer in this group still need to be 
thoroughly investigated, aiming for a most secure release of women from screening. Previous 
study found that women who have had carcinoma in situ at any point of life exhibited increased 
risk of cervical cancer especially at older ages (186). Other factors such as immune deficiency 
and history of HPV infection could also be examined. The collective evidence may clue us in 
an individualised screening strategy, which would acknowledge both efficiency and cost, and 
face the potential mode of healthcare in the future when abundant information from individual 
and environment becomes increasingly available. 
Cervical screening programme in Sweden and many countries over the world is switching to 
HPV primary screening. Our studies presented not only a benchmark of the success and 
weaknesses from conventional screening, but also an evaluation framework that can be used 
for repeat performance comparable over time. In the near future, routine case-control audit 
needs to be carried out in HPV primary screening programme to examine whether implemented 
improvements work as expected.  
After ten years’ administration of HPV vaccination, vaccinated cohorts are gradually entering 
screening ages. Currently the cohorts reaching screening ages have low vaccination coverage, 
but in the near future for the cohorts who underwent the catch-up or even school-based 
vaccination, the adapted screening strategy warrants series of research, such as whether HPV 
primary screening can be performed under age 30 due to potential improved positive predictive 
value; could the interval be extended, etc. There are also ongoing discussions about population 
strategy according to coverage of vaccination by cohort versus individualised strategy referring 
to vaccination history of each woman. In addition, the screening attendance after being 
vaccinated in population deserves attention. Current evidence shows that the unvaccinated 
group participated less in screening compared to the vaccinated group, but it was from the 
cohorts with very low vaccine coverage thus would reflect impact of health consciousness 
(187).  The scenario in birth cohorts undergone catch-up or school-based vaccination is of great 
interest. If the same pattern is followed, given the lower vaccine uptake in family of foreign-
born and lower socioeconomic background, the social disparity in cervical cancer in the future 
might be enlarged, for which more effective approaches to reach these groups would become 
critical. 
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Although observational study is considered inferior to systematic review and randomised 
control trial in evidence hierarchy under the framework of Evidence Based Medicine, 
randomised trial is not always feasible in terms of ethics, time consumption and economic cost. 
Meanwhile, along with the rapid development of information technology, real-life data is 
becoming increasingly available with strengthened quantity and quality. This thesis work 
would serve as an attempt of utilising the large-scale observational data. In the future, 
exploration of sufficient use of real-life data with rigorous study design may efficiently benefit 
the evidence body for medical and healthcare decision-making. 
 
  49 
9 FUNDING 
This thesis was funded by: 
 China Scholarship Council (国家留学基金委) 
 The Swedish Foundation for Strategic Research (Stiftelsen för Strategisk Forskning) 
 The Swedish Cancer Society (Cancerfonden) 
 The Swedish Research Council (Vetenskapsrådet) 
 
 
  51 
10 ACKNOWLEDGEMENTS 
It was the most enjoyable and rewarding five years in the first 30 years of my life. I developed 
not only knowledge and skills, but also, more importantly, the way of thinking, the passion for 
exploration, and the attitude to life. All of you, who make to this page, helped me through the 
treasured journey. 
To my main supervisor Pär Sparén, being your student is undoubtedly my great fortune. 
Thank you for providing me enormous space to explore, encouraging me at every single 
attempt, and advising me with your knowledgeable, technical mind. You do not hold students’ 
hands all the time, but your hands are always by our sides. I therefore enjoyed the whole 
adventure, with freedom and a strong sense of safety. And, thank you for guiding me to the 
fantastic world of data, a place I would like to live for the rest of my life! 
To my co-supervisor Lisen Arnheim-Dahlström, thank you for being a perceptual and strict 
supervisor. You detected my confidence and hesitation, helped me with a push when I slacked 
off, and motivated me with your perseverance. And thank you for organising those group 
activities in which I had a lot of fun. 
To my co-supervisor Karin Sundström, thank you for being a down-to-earth supervisor. You 
helped me break down complicated questions, and guided me to solve them practically. I am 
very grateful for your advice at work with your logical, analytical and critical thinking, and 
also your support to my personal life with your understanding and consolation. 
To Bengt Andrae, my supervisor although not written on the official document, thank you for 
being my teacher of gynaecology, and thank you for bringing up innumerable clinical questions 
to research which helped build my thesis, but more importantly bring along benefit for the 
entire women population. I deeply admire your enthusiasm, not only for conquering cervical 
cancer, but also for exploring the life. You are my role model for keeping a forever-young heart. 
To Fang Fang, thank you for bringing me to Pär directly at the first time we met, which opened 
me the door to this wonderful journey. And thank you for being the chairperson of my defense, 
to witness me reaching the destination. Your warm heart always comforts me, and your 
devotion to science inspires me on my career pursuit. 
To my statisticians Alexander Ploner and Peter Ström. Alex, thank you for your critical and 
rigid mind, which guided me to scrutinise every solution. Your advice greatly expanded and 
deepened my understanding of statistics, and enlightened me on the statistical thinking. Peter, 
thank you for your thinking from the outside of the box, and for your challenge on many 
stereotypes in the conventional analyses. You pushed our studies to a higher standard from the 
beginning. 
To Professor Joakim Dillner, thank you for your advice and revisions on our studies. I really 
appreciated your push for broader attention of our work, and feel sincerely grateful for your 
constant encouragement. To Kristina Elfgren, visiting your gynaecological clinic for a field 
 52 
learning was one of the worthwhile activities in my PhD study. Thank you for inviting me and 
guiding me in that morning. Also thank you for being in my halftime committee, for many 
enjoyable discussions/chatting at conferences, and for your great help during my illness. 
To the project coordinator Sara Nordqvist Kleppe, thank you for your very organised work 
for collecting important samples and data. Also thank you for being a considerate friend and 
officemate to share work and personal experiences. To our data manager Pouran Almstedt, 
thank you for your careful work on building and maintaining the ACCES database. To our 
previous data manager Mariam Lashkariani, thank you for providing the first translation 
matrix of the complicated Pap smear codes. To the late Peter Olausson, please receive my 
belated gratitude for your dedicated work on the structured translation system of Pap smear 
code. 
To our group members and friends Miriam Elfström, Eva Herweijer, Favelle Lamb, Jiayao 
Lei, Amy Levál, Olof Grönlund, Inga Velicko and Nicolas Baltzer. Miriam and Eva, thank 
you so much for your generous share of knowledge, ideas and skills which helped me greatly 
on my study. And thank you for those enjoyable meals, fun activities, and for being with you 
at some important moments of our life. Favelle, thank you for the daily talks of our studies, the 
lunchtime chatting about personal life, and the lovely parties at your place. Especially thank 
you for your tremendous help on my English writing. Jiayao, thank you for the pleasant 
collaboration on the audit work, and for the fun leisure time during conferences. I do feel we 
have many in common. Amy, thank you for sharing your experiences of previous study and 
current work. I am grateful for your warm care and encouragement for my study through the 
years. Olof and Inga, thank you for the enlightening discussions in group meetings, and good 
time at lunches and group activities. Nicolas, thank you for such a lot of fun during conferences. 
To people from the ACCES group in Huddinge, Camila Lagheden, Carina Eklund and 
Maria Hortlund, thank you for being by my side at conference presentations, and thank you 
for those enjoyable meals during conferences and after our meetings. To co-authors Björn 
Strander and Gudrun Broberg, thank you for involving me in the study of socioeconomic 
determinants of cervical screening attendance. It has been a delightful learning. 
To my lovely MEB friends: Donghao Lu, thank you for sharing your knowledge and opinions 
from perspectives of a gynaecologist for our collaboration and for helping my studies. Jie Song 
and Ruoqing Chen, we came to the department at almost the same time. Thank you for the 
discussions at courses, for sharing experiences and encouragement at important time points of 
our studies. Sarah Bergen, thank you for having been a great officemate. I enjoyed the chatting 
with you at that time, as well as those later on which relaxed me a lot during some stressful 
time. Tong Gong, Bojing Liu and Shuyang Yao, thank you for the daily “brain-burning” 
discussions of study designs, for your deep, emotional support during my tough time, and for 
the cheerful swimming and gym exercise together. Carolyn Cesta, thank you for organising 
those impressive activities, for those cozy girls’ dinners, and for your warm regards to me and 
to my studies. Linda Abrahamsson, thank you for inviting me to your lovely party, and for 
your great help on my pre-dissertation. To the lovely MEB Chinese friends Huan Song, 
  53 
Jianwei Zhu, Qi Chen, Chen Suo, Jiaqi Huang, Zhiwei Liu, Zheng Chang, Ci Song, Fei 
Yang, Yiqiang Zhan, Xingrong Liu, Tingting Huang, Haomin Yang, Wei He, Xu Chen, 
Qing Shen, Yuanjun Ma, and many more, thank you for making a solidary, family-like group 
with warm hearts and mutual helps. Thanks Kathleen Bokenberger and Hannah Bower for 
friendship. Many thanks to Marie Reilly, Judi Pawitan, Anna Johansson and Mark 
Clements for the courses, teaching and encouragements. To the lovely, respectable MEB 
administrative staff, thank you for making the department exceptionally supportive and 
affectionate. Especially thanks Gunilla Sonnebring, Erika Nordenhagen and Frank 
Pettersson, for the daily support, and for organising those fantastic department activities; 
Gunilla Nilsson Roos, for considerately organising the outstanding MEB courses; Camilla 
Ahlqvist, for being the world best education administrator! As well as the MEB IT group, 
thank you for making such a professional IT environment. 
To my close friends in Sweden, Chang Liu, Xiao Tang, Meng Chen&Jingying Yuan, Tian 
Li&John Thilén, Yiqiao Wang&Yan Xu, you were initially my “friends-in-law”, but we 
became close friends very soon, as we are such in same “channel”. Together with Xiaofei Li, 
Jing Guo, Xintong Jiang and Yixin Wang, thank you all for such a lot of entertaining meals, 
travels, board games, and tremendous helps. Na Guan and Jianren Song, thank you so much 
for your generous help when my husband and I were almost homeless. We then got along very 
well as we share a lot in common. Thank you for your warm care and the special, best wish. 
And thanks Qing Cheng, Yuan Xu, Qinzi Yan&Shuo Liu and other friends I know in Sweden, 
for many fun activities. Thanks Yi Wang&Lu Wang for being very good neighbours. Jing 
Jin, Pujiang Li, and Xu Wei, thank you for every reunion time in Beijing, and for being my 
long-last friends. 
Special thanks to my supervisor in master programme, Tuohong Zhang. Thank you for being 
a considerate, family-like and friend-like supervisor. Your encouragement made me 
determined to pursue PhD abroad. And your continuous concern supported me throughout 
these years. I enjoyed the cozy time with you in your apartment in Geneva, and all the treasured 
talks every time I went back to Beijing. Your conscientiousness and open mind deeply 
enlighten me on my work and life. 





To my beloved husband, Xiaoyuan Ren. Most of the things that finally made through the five 
years to this book were not predictable at the beginning. But if only one thing was, I knew that 
was you being by my side. Word cannot express how much gratitude I have for your immense 
support. You are the only one to me, in the past, at present, and in the future. 
 
  55 
11 REFERENCES 
1.  Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, 
Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: 
International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr 
2.  Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical 
cancer incidence: Impact of screening against changes in disease risk factors. Eur J Cancer. 2013 
Oct;49(15):3262–73.  
3.  Vaccarella S, Franceschi S, Engholm G, Lönnberg S, Khan S, Bray F. 50 years of screening in the 
Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014 Aug 
26;111(5):965–9.  
4.  Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the 
UK audit of screening histories. Br J Cancer. 2003;89(1):88–93.  
5.  Andrae B, Kemetli L, Sparén P, Silfverdal L, Strander B, Ryd W, et al. Screening-Preventable 
Cervical Cancer Risks: Evidence From a Nationwide Audit in Sweden. J Natl Cancer Inst. 2008 
May 7;100(9):622–9.  
6.  Lönnberg S, Anttila A, Luostarinen T, Nieminen P. Age-Specific Effectiveness of the Finnish 
Cervical Cancer Screening Programme. Cancer Epidemiol Biomarkers Prev. 2012 Aug 
1;21(8):1354–61.  
7.  Bray F, Carstensen B, Møller H, Zappa M, Žakelj MP, Lawrence G, et al. Incidence Trends of 
Adenocarcinoma of the Cervix in 13 European Countries. Cancer Epidemiol Biomarkers Prev. 
2005 Sep 1;14(9):2191–9.  
8.  Paavonen J, Naud P, Salmerón J, Wheeler C, Chow S-N, Apter D, et al. Efficacy of human 
papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer 
caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study 
in young women. The Lancet. 2009 Jul 31;374(9686):301–14.  
9.  Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a 
population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC 
Med. 2013;11:227.  
10.  Crowe E, Pandeya N, Brotherton JML, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of 
quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-
control study nested within a population based screening programme in Australia. BMJ. 2014 
Mar 4;348:g1458.  
11.  Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Quadrivalent 
HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A 
population-based study. Int J Cancer. 2016 Jun 15;138(12):2867–74.  
12.  Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence 
of mucosal and cutaneous human papillomavirus types. Virology. 2013 Oct 1;445(1):224–31.  
13.  Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic 
Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med. 
2003 Feb 6;348(6):518–27.  
14.  Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, Sanjosé S de. Cervical Human 
Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal 
Cytological Findings. J Infect Dis. 2010 Dec 15;202(12):1789–99.  
15.  WHO | Human papillomavirus (HPV) and cervical cancer [Internet]. WHO. [cited 2017 Nov 12]. 
Available from: http://www.who.int/mediacentre/factsheets/fs380/en/ 
 56 
16.  Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and 
cervical cancer. The Lancet. 2007 Sep 14;370(9590):890–907.  
17.  Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved 
issues. Nat Rev Cancer. 2007 Jan 1;7(1):nrc2050.  
18.  Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol 
Pathol Off J Int Soc Gynecol Pathol. 1993 Apr;12(2):186–92.  
19.  Louie KS, de Sanjose S, Diaz M, Castellsagué X, Herrero R, Meijer CJ, et al. Early age at first 
sexual intercourse and early pregnancy are risk factors for cervical cancer in developing 
countries. Br J Cancer. 2009 Mar 10;100(7):1191–7.  
20.  International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical Carcinoma 
and Sexual Behavior: Collaborative Reanalysis of Individual Data on 15,461 Women with 
Cervical Carcinoma and 29,164 Women without Cervical Carcinoma from 21 Epidemiological 
Studies. Cancer Epidemiol Biomarkers Prev. 2009 Apr 1;18(4):1060–9.  
21.  International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the 
cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with 
carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 
epidemiological studies. Int J Cancer. 2006 Mar 15;118(6):1481–95.  
22.  International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma 
and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with 
cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological 
studies. Int J Cancer. 2006 Sep 1;119(5):1108–24.  
23.  International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and 
hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with 
cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. The 
Lancet. 2007 Nov 16;370(9599):1609–21.  
24.  Simen-Kapeu A, Kataja V, Yliskoski M, Syrjanen K, Dillner J, Koskela P, et al. Smoking impairs 
human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV 
infection. Scand J Infect Dis. 2008;40(9):745–51.  
25.  Burd EM. Human Papillomavirus and Cervical Cancer. Clin Microbiol Rev. 2003 Jan;16(1):1–
17.  
26.  Austin RM, Ramzy I. Increased detection of epithelial cell abnormalities by liquid-based 
gynecologic cytology preparations - A review of accumulated data. Acta Cytol. 1998 
Feb;42(1):178–84.  
27.  Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the 
Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic 
review. Ann Intern Med. 2000 May 16;132(10):810–9.  
28.  Cuzick J, Clavel C, Petry K-U, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the 
European and North American studies on HPV testing in primary cervical cancer screening. Int J 
Cancer. 2006 Sep 1;119(5):1095–101.  
29.  Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et al. Identifying 
women with cervical neoplasia - Using human papillomavirus DNA testing for equivocal 
Papanicolaou results. Jama-J Am Med Assoc. 1999 May 5;281(17):1605–10.  
30.  Mayrand M-H, Koushik A. Atypical glandular cells on cervical cytology. BMJ. 2016 Feb 
11;352:i723.  
31.  Elfström KM, Smelov V, Johansson ALV, Eklund C, Nauclér P, Arnheim-Dahlström L, et al. 
Long term duration of protective effect for HPV negative women: follow-up of primary HPV 
screening randomised controlled trial. BMJ. 2014 Jan 16;348:g130.  
  57 
32.  Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV 
DNA testing and liquid based cytology over three rounds of primary cervical screening: extended 
follow up in the ARTISTIC trial. Eur J Cancer Oxf Engl 1990. 2011 Apr;47(6):864–71.  
33.  Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, et al. Long term predictive 
values of cytology and human papillomavirus testing in cervical cancer screening: joint European 
cohort study. BMJ. 2008 Oct 13;337:a1754.  
34.  Arbyn M, Rebolj M, De Kok IMCM, Fender M, Becker N, O’Reilly M, et al. The challenges of 
organising cervical screening programmes in the 15 old member states of the European Union. 
Eur J Cancer. 2009 Oct 1;45(15):2671–8.  
35.  Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J 
Cancer. 2001 Oct 15;94(2):153–6.  
36.  Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of 
cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893–917.  
37.  Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, et al. Cervical cancer screening 
programmes and policies in 18 European countries. Br J Cancer. 2004 Jul 27;91(5):6602069.  
38.  Dillner J. Cervical cancer screening in Sweden. Eur J Cancer. 2000 Nov;36(17):2255–9.  
39.  Swedish National Cervial Screening Registry: Annual Report 2017 [Internet]. [cited 2017 Nov 
14]. Available from: http://www.nkcx.se/templates/_rsrapport_2017.pdf 
40.  Vizcaino AP, Moreno V, Bosch FX, Muñoz N, Barros-Dios XM, Borras J, et al. International 
trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer. 2000 May 
1;86(3):429–35.  
41.  Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Møller H, et al. Trends in Cervical 
Squamous Cell Carcinoma Incidence in 13 European Countries: Changing Risk and the Effects of 
Screening. Cancer Epidemiol Biomarkers Prev. 2005 Mar 1;14(3):677–86.  
42.  Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and 
adenosquamous carcinoma in younger women. Can Med Assoc J. 2001 Apr 17;164(8):1151–2.  
43.  Lönnberg S, Hansen BT, Haldorsen T, Campbell S, Schee K, Nygård M. Cervical cancer 
prevented by screening: Long-term incidence trends by morphology in Norway. Int J Cancer. 
2015 Apr 1;n/a-n/a.  
44.  Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the 
cervix in England. The Lancet. 2001 May 12;357(9267):1490–3.  
45.  Sigurdsson K. The Icelandic and Nordic cervical screening programs, Trends in incidence and 
mortality rates through 1995. Acta Obstet Gynecol Scand. 1999 Jun 1;78(6):478–85.  
46.  Wang SS, Sherman ME, Hildesheim A, Lacey JV, Devesa S. Cervical adenocarcinoma and 
squamous cell carcinoma incidence trends among white women and black women in the United 
States for 1976–2000. Cancer. 2004 Mar 1;100(5):1035–44.  
47.  Gunnell AS, Ylitalo N, Sandin S, Sparén P, Adami H-O, Ripatti S. A Longitudinal Swedish Study 
on Screening for Squamous Cell Carcinoma and Adenocarcinoma: Evidence of Effectiveness and 
Overtreatment. Cancer Epidemiol Prev Biomark. 2007 Dec 1;16(12):2641–8.  
48.  Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and 
adenocarcinoma of cervix--worldwide. Asian Pac J Cancer Prev APJCP. 2009 Dec;10(4):645–50.  
49.  Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer. 2009 
Aug 1;125(3):525–9.  
50.  Plaxe SC, Saltzstein SL. Estimation of the Duration of the Preclinical Phase of Cervical 
Adenocarcinoma Suggests That There Is Ample Opportunity for Screening. Gynecol Oncol. 1999 
Oct;75(1):55–61.  
 58 
51.  The International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of 
risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: 
Collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 
1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007 Feb 
15;120(4):885–91.  
52.  Castellsagué X, Díaz M, Sanjosé S de, Muñoz N, Herrero R, Franceschi S, et al. Worldwide 
Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for 
Screening and Prevention. J Natl Cancer Inst. 2006 Mar 1;98(5):303–15.  
53.  Bosch F, Manos M, Munoz N, Sherman M, Jansen A, Peto J, et al. Prevalence of Human 
Papillomavirus in Cervical-Cancer - a Worldwide Perspective. J Natl Cancer Inst. 1995 Jun 
7;87(11):796–802.  
54.  de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human 
papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional 
worldwide study. Lancet Oncol. 2010 Nov;11(11):1048–56.  
55.  Dahlström LA, Ylitalo N, Sundström K, Palmgren J, Ploner A, Eloranta S, et al. Prospective 
study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer. 2010 Oct 
15;127(8):1923–30.  
56.  Mitchell H, Medley G, Gordon I, Giles G. Cervical cytology reported as negative and risk of 
adenocarcinoma of the cervix: no strong evidence of benefit. Br J Cancer. 1995 Apr;71(4):894–7.  
57.  Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of cytological 
screening for adenocarcinomas and shorter protection for younger women: the results of a case–
control study in Florence. Br J Cancer. 2004 Mar 30;90(9):1784–6.  
58.  Chen Y-Y, You S-L, Koong S-L, Liu J, Chen C-A, Chen C-J. Screening Frequency and Atypical 
Cells and the Prediction of Cervical Cancer Risk: Obstet Gynecol. 2014 May;123(5):1003–11.  
59.  Castanon A, Landy R, Sasieni PD. Is cervical screening preventing adenocarcinoma and 
adenosquamous carcinoma of the cervix? Int J Cancer. 2016 Sep 1;139(5):1040–5.  
60.  Ashfaq R, Gibbons D, Vela C, Saboorian MH, Iliya F. ThinPrep Pap Test. Accuracy for glandular 
disease. Acta Cytol. 1999 Feb;43(1):81–5.  
61.  Nieminen P, Kallio M, Hakama M. The Effect of Mass Screening on Incidence and Mortality of 
Squamous and Adenocarcinoma of Cervix Uteri. Obstet Gynecol. 1995 Jun;85(6):1017–21.  
62.  Schnatz PF, Guile M, OʼSullivan DM, Sorosky JI. Clinical Significance of Atypical Glandular 
Cells on Cervical Cytology: Obstet Gynecol. 2006 Mar;107(3):701–8.  
63.  Soloman D. The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses: 
Developed and approved at the national cancer institute workshop in Bethesda, MD, December 
12–13, 1988. Diagn Cytopathol. 1989 Jul 1;5(3):331–4.  
64.  Broder S. RApid communication—the bethesda system for reporting cervical/vaginal cytologic 
diagnoses—report of the 1991 bethesda workshop. JAMA. 1992 Apr 8;267(14):1892–1892.  
65.  Solomon D, Davey D, Kurman R, et al. The 2001 bethesda system: Terminology for reporting 
results of cervical cytology. JAMA. 2002 Apr 24;287(16):2114–9.  
66.  Wright Jr TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus 
guidelines for the management of women with abnormal cervical cancer screening tests. Am J 
Obstet Gynecol. 2007 Oct;197(4):346–55.  
67.  Cheng W-F, Chen Y-L, You S-L, Chen C-J, Chen Y-C, Hsieh C-Y, et al. Risk of gynaecological 
malignancies in cytologically atypical glandular cells: follow-up study of a nationwide screening 
population. BJOG Int J Obstet Gynaecol. 2011 Jan 1;118(1):34–41.  
  59 
68.  Kim TJ, Kim HS, Park CT, Park IS, Hong SR, Park JS, et al. Clinical Evaluation of Follow-up 
Methods and Results of Atypical Glandular Cells of Undetermined Significance (AGUS) 
Detected on Cervicovaginal Pap Smears. Gynecol Oncol. 1999 May;73(2):292–8.  
69.  Kennedy AW, Salmieri SS, Wirth SL, Biscotti CV, Tuason LJ, Travarca MJ. Results of the 
Clinical Evaluation of Atypical Glandular Cells of Undetermined Significance (AGCUS) 
Detected on Cervical Cytology Screening. Gynecol Oncol. 1996 Oct;63(1):14–8.  
70.  Zweizig S, Noller K, Reale F, Collis S, Resseguie L. Neoplasia Associated with Atypical 
Glandular Cells of Undetermined Significance on Cervical Cytology. Gynecol Oncol. 1997 
May;65(2):314–8.  
71.  Zhao C, Florea A, Onisko A, Austin RM. Histologic follow-up results in 662 patients with Pap 
test findings of atypical glandular cells: Results from a large academic womens hospital 
laboratory employing sensitive screening methods. Gynecol Oncol. 2009 Sep;114(3):383–9.  
72.  Chhieng DC, Elgert PA, Cangiarella JF, Cohen J-M. Clinical Significance of Atypical Glandular 
Cells of Undetermined Significance. Acta Cytol. 2000;44(4):557–66.  
73.  Goff BA, Atanasoff P, Brown E, Muntz HG, Bell DA, Rice LW. Endocervical glandular atypia in 
Papanicolaou smears. Obstet Gynecol. 1992 Jan;79(1):101–4.  
74.  Nasuti JF, Fleisher SR, Gupta PK. Atypical glandular cells of undetermined significance 
(AGUS): Clinical considerations and cytohistologic correlation. Diagn Cytopathol. 2002 Mar 
1;26(3):186–90.  
75.  Ulker V, Numanoglu C, Akyol A, Kuru O, Akbayir O, Erim A, et al. Analyses of atypical 
glandular cells re-defined by the 2006 Bethesda System: histologic outcomes and clinical 
implication of follow-up management. Eur J Gynaecol Oncol. 2013;34(5):457–61.  
76.  Geier CS, Wilson M, Creasman W. Clinical evaluation of atypical glandular cells of 
undetermined significance. Am J Obstet Gynecol. 2001 Jan;184(2):64–9.  
77.  Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Dysplasia Associated With 
Atypical Glandular Cells on Cervical Cytology: Obstet Gynecol. 2005 Mar;105(3):494–500.  
78.  Adhya AK, Mahesha V, Srinivasan R, Nijhawan R, Rajwanshi A, Suri V, et al. Atypical 
glandular cells in cervical smears: histological correlation and a suggested plan of management 
based on age of the patient in a low-resource setting. Cytopathology. 2009 Dec 1;20(6):375–9.  
79.  Asciutto KC, Henic E, Forslund O, Bjelkenkrantz K, Borgfeldt C. Age Influences the Clinical 
Significance of Atypical Glandular Cells on Cytology. Anticancer Res. 2015 Feb 1;35(2):913–9.  
80.  Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated 
consensus guidelines for the management of abnormal cervical cancer screening tests and cancer 
precursors. Obstet Gynecol. 2013 Apr;121(4):829–46.  
81.  Silfverdal L, Kemetli L, Andrae B, Sparén P, Ryd W, Dillner J, et al. Risk of invasive cervical 
cancer in relation to management of abnormal Pap smear results. Am J Obstet Gynecol. 2009 
Aug;201(2):188.e1-7.  
82.  Gustafsson L, Pontén J, Bergstrôm R, Adami H-O. International incidence rates of invasive 
cervical cancer before cytological screening. Int J Cancer. 1997 Apr 10;71(2):159–65.  
83.  Plummer M, Peto J, Franceschi S, ; on behalf of the International Collaboration of 
Epidemiological Studies of Cervical Cancer. Time since first sexual intercourse and the risk of 
cervical cancer. Int J Cancer. 2012 Jun 1;130(11):2638–44.  
84.  Gustafsson L, Pontén J, Zack M, Adami H-O. International incidence rates of invasive cervical 
cancer after introduction of cytological screening. Cancer Causes Control. 1997 Sep 1;8(5):755–
63.  
 60 
85.  Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, Dehovitz JA, et al. Declining 
Prevalence of Cervicovaginal Human Papillomavirus Infection With Age Is Independent of Other 
Risk Factors. Sex Transm Dis. 1996 Aug;23(4):333–341.  
86.  Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A 
Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence 
in Guanacaste, Costa Rica. J Infect Dis. 2005 Jun 1;191(11):1808–16.  
87.  Smith JS, Melendy A, Rana RK, Pimenta JM. Age-Specific Prevalence of Infection with Human 
Papillomavirus in Females: A Global Review. J Adolesc Health. 2008 Oct 1;43(4, 
Supplement):S5.e1-S5.e62.  
88.  Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Prevalence, 
Acquisition, and Clearance of Cervical Human Papillomavirus Infection among Women with 
Normal Cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res. 2008 Nov 
1;68(21):8813–24.  
89.  Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. 
Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia 
Grade 2/3: Critical Role of Duration of Infection. J Natl Cancer Inst. 2010 Mar 3;102(5):315–24.  
90.  Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011 Dec 
1;121(12):4593–9.  
91.  Smith E m., Johnson S r., Ritchie J m., Feddersen D, Wang D, Turek L p., et al. Persistent HPV 
infection in postmenopausal age women. Int J Gynecol Obstet. 2004 Nov 1;87(2):131–7.  
92.  Gustafsson L, Sparen P, Gustafsson M, Pettersson B, Wilander E, Bergstrom R, et al. Low 
efficiency of cytologic screening for cancer in situ of the cervix in older women. Int J Cancer. 
1995;63(6):804–9.  
93.  Parkin DM, Leach K, Cobb P, Clayden AD. Cervical cytology screening in two Yorkshire areas: 
Results of testing. Public Health. 1982 Jan;96(1):3–14.  
94.  Gustafsson L, Adami HO. Natural history of cervical neoplasia: consistent results obtained by an 
identification technique. Br J Cancer. 1989 Jul;60(1):132–41.  
95.  Evans DM, Hibbard BM, Jones JM, Sweetnam P. The Cardiff Cervical Cytology Study: 
prevalence of cytological grades and initial histological findings. Br Med J Clin Res Ed. 1981 Feb 
28;282(6265):689–91.  
96.  Blesch KSMS, Prohaska TR. Cervical cancer screening in older women: Issues and interventions. 
Cancer Nurs. 1991 Jun;14(3):141–7.  
97.  Fletcher A. Screening for cancer of the cervix in elderly women. The Lancet. 1990 Jan 
13;335(8681):97–9.  
98.  Dunn JE, Martin PL. Morphogenesis of cervical cancer. Findings from San Diego County 
Cytology Registry. Cancer. 1967 Nov 1;20(11):1899–906.  
99.  Castañón A, Landy R, Cuzick J, Sasieni P. Cervical Screening at Age 50–64 Years and the Risk 
of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study. PLOS 
Med. 2014 Jan 14;11(1):e1001585.  
100. Lynge E, Rygaard C, Baillet MV-P, Dugué P-A, Sander BB, Bonde J, et al. Cervical cancer 
screening at crossroads. APMIS. 2014 Aug 1;122(8):667–73.  
101. Elfström KM, Arnheim-Dahlström L, von Karsa L, Dillner J. Cervical cancer screening in 
Europe: Quality assurance and organisation of programmes. Eur J Cancer. 2015 May 
1;51(8):950–68.  
102. Lynge E, Lönnberg S, Törnberg S. Cervical cancer incidence in elderly women-biology or 
screening history? Eur J Cancer. 2017 Mar;74:82–8.  
  61 
103. Kulasingam SL, Havrilesky LJ, Ghebre R, Myers ER. Screening for Cervical Cancer: A 
Modeling Study for the US Preventive Services Task Force. J Low Genit Tract Dis. 2013 
Apr;17(2):193–202.  
104. Flannelly G, Monaghan J, Cruickshank M, Duncan I, Johnson J, Jordan J, et al. Cervical 
screening in women over the age of 50: results of a population-based multicentre study. BJOG Int 
J Obstet Gynaecol. 2004 Apr 1;111(4):362–8.  
105. Schiller JT, Lowy DR, Markowitz LE. 16 - Human papillomavirus vaccines. In: Offit SAPAOA, 
editor. Vaccines (Sixth Edition). London: W.B. Saunders; 2013. p. 235–56.  
106. World Health Organisation. Meeting of the Strategic Advisory Group of Experts on 
immunization, April 2014 – conclusions and recommendations. Wkly Epidemiol Rec. 
89(21):221–36.  
107. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a 
bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 
16 and 18 in young women: a randomised controlled trial. The Lancet. 2004 Nov 
13;364(9447):1757–65.  
108. Villa LL, Ault KA, Giuliano AR, Costa RLR, Petta CA, Andrade RP, et al. Immunologic 
responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, 
and 18. Vaccine. 2006 Jul 7;24(27–28):5571–83.  
109. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen O-E, et al. High sustained 
efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like 
particle vaccine through 5 years of follow-up. Br J Cancer. 2006 Dec 4;95(11):1459–66.  
110. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen O-E, et al. 
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade 
cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled 
trial. BMJ. 2010 Jul 20;341:c3493.  
111. Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, et al. A 
pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 
6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 
Phila Pa. 2009 Oct;2(10):868–78.  
112. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human 
papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel 
surveillance data. Lancet Infect Dis. 2011 Jan 1;11(1):39–44.  
113. Leval A, Herweijer E, Arnheim-Dahlström L, Walum H, Frans E, Sparén P, et al. Incidence of 
Genital Warts in Sweden Before and After Quadrivalent Human Papillomavirus Vaccine 
Availability. J Infect Dis. 2012 Sep 15;206(6):860–6.  
114. Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, et al. Genital warts in young 
Australians five years into national human papillomavirus vaccination programme: national 
surveillance data. BMJ. 2013 Apr 18;346:f2032.  
115. Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. Human 
Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, 
Scotland, 2009–2013. Emerg Infect Dis. 2016 Jan;22(1):56–64.  
116. Drolet M, Bénard É, Boily M-C, Ali H, Baandrup L, Bauer H, et al. Population-level impact and 
herd effects following human papillomavirus vaccination programmes: a systematic review and 
meta-analysis. Lancet Infect Dis. 2015 May;15(5):565–80.  
117. Schiller JT, Castellsagué X, Garland SM. A Review of Clinical Trials of Human Papillomavirus 
Prophylactic Vaccines. Vaccine. 2012 Nov 20;30(Supplement 5):F123–38.  
 62 
118. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and Safety of Prophylactic Vaccines 
against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-
Analysis. BMC Infect Dis. 2011 Jan 12;11:13.  
119. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al. Monitoring the safety of quadrivalent 
human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 
26;29(46):8279–84.  
120. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al. Human papillomavirus 
vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety 
monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep. 2014 Jul;63(29):620–4.  
121. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, 
neurological, and venous thromboembolic adverse events after immunisation of adolescent girls 
with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 
2013 Oct 9;347:f5906.  
122. Scheller N, Svanström H, Pasternak B, et al. QUadrivalent hpv vaccination and risk of multiple 
sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015 Jan 
6;313(1):54–61.  
123. Scheller NM, Pasternak B, Mølgaard-Nielsen D, Svanström H, Hviid A. Quadrivalent HPV 
Vaccination and the Risk of Adverse Pregnancy Outcomes. N Engl J Med. 2017 Mar 
30;376(13):1223–33.  
124. Grönlund O, Herweijer E, Sundström K, Arnheim-Dahlström L. Incidence of new-onset 
autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent 
human papillomavirus vaccination: a cohort study. J Intern Med. 2016 Dec 1;280(6):618–26.  
125. Lantz PM. Socioeconomic Status and Health Care. In: Baltes NJSB, editor. International 
Encyclopedia of the Social & Behavioral Sciences [Internet]. Oxford: Pergamon; 2001 [cited 
2015 May 2]. p. 14558–62. Available from: 
http://www.sciencedirect.com/science/article/pii/B0080430767038286 
126. Shippee ND, Mullan RJ, Nabhan M, Kermott CA, Hagen PT, Rhodes DJ, et al. Adherence to 
Preventive Recommendations: Experience of a Cohort Presenting for Executive Health Care. 
Popul Health Manag. 2011 Nov 17;15(2):65–70.  
127. Newacheck PW, Hung YY, Jane Park M, Brindis CD, Irwin CE. Disparities in Adolescent 
Health and Health Care: Does Socioeconomic Status Matter? Health Serv Res. 2003 Oct 
1;38(5):1235–52.  
128. Derose KP, Escarce JJ, Lurie N. Immigrants And Health Care: Sources Of Vulnerability. Health 
Aff (Millwood). 2007 Sep 1;26(5):1258–68.  
129. Dutton DB. Explaining the low use of health services by the poor: costs, attitudes, or delivery 
systems? Am Sociol Rev. 1978 Jun;43(3):348–68.  
130. Lenselink CH, Gerrits MMJG, Melchers WJG, Massuger LFAG, van Hamont D, Bekkers RLM. 
Parental acceptance of Human Papillomavirus vaccines. Eur J Obstet Gynecol Reprod Biol. 2008 
Mar 1;137(1):103–7.  
131. Dahlström LA, Tran TN, Lundholm C, Young C, Sundström K, Sparén P. Attitudes to HPV 
vaccination among parents of children aged 12-15 years—A population-based survey in Sweden. 
Int J Cancer. 2010 Jan 15;126(2):500–7.  
132. Sundström K, Tran TN, Lundholm C, Young C, Sparén P, Dahlström LA. Acceptability of HPV 
vaccination among young adults aged 18–30 years–a population based survey in Sweden. 
Vaccine. 2010 Nov 3;28(47):7492–500.  
133. Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. Human Papilloma Virus vaccine and 
cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health. 
2007 Oct 25;7:304.  
  63 
134. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: A theory-informed, systematic 
review. Prev Med. 2007 Aug 1;45(2):107–14.  
135. Tung ILY, Machalek DA, Garland SM. Attitudes, Knowledge and Factors Associated with 
Human Papillomavirus (HPV) Vaccine Uptake in Adolescent Girls and Young Women in 
Victoria, Australia. PLOS ONE. 2016 Aug 26;11(8):e0161846.  
136. Rondy M, van Lier A, van de Kassteele J, Rust L, de Melker H. Determinants for HPV vaccine 
uptake in the Netherlands: A multilevel study. Vaccine. 2010 Feb 25;28(9):2070–5.  
137. Slåttelid Schreiber SM, Juul KE, Dehlendorff C, Kjær SK. Socioeconomic Predictors of Human 
Papillomavirus Vaccination Among Girls in the Danish Childhood Immunization Program. J 
Adolesc Health. 2015 Apr 1;56(4):402–7.  
138. Pruitt SL, Schootman M. Geographic disparity, area poverty, and human papillomavirus 
vaccination. Am J Prev Med. 2010 May;38(5):525–33.  
139. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination 
coverage among adolescents aged 13-17 years --- United States, 2009. MMWR Morb Mortal 
Wkly Rep. 2010 Aug 20;59(32):1018–23.  
140. Polonijo AN, Carpiano RM. Social inequalities in adolescent human papillomavirus (HPV) 
vaccination: A test of fundamental cause theory. Soc Sci Med. 2013 Apr;82:115–25.  
141. Feiring B, Laake I, Molden T, Cappelen I, Håberg SE, Magnus P, et al. Do parental education 
and income matter? A nationwide register-based study on HPV vaccine uptake in the school-
based immunisation programme in Norway. BMJ Open. 2015 May 1;5(5):e006422.  
142. Ogilvie G, Anderson M, Marra F, McNeil S, Pielak K, Dawar M, et al. A Population-Based 
Evaluation of a Publicly Funded, School-Based HPV Vaccine Program in British Columbia, 
Canada: Parental Factors Associated with HPV Vaccine Receipt. PLoS Med [Internet]. 2010 May 
[cited 2016 Jan 4];7(5). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864299/ 
143. Hansen BT, Campbell S, Burger E, Nygård M. Correlates of HPV vaccine uptake in school-
based routine vaccination of preadolescent girls in Norway: A register-based study of 90,000 girls 
and their parents. Prev Med. 2015 Aug;77:4–10.  
144. Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: Considerations for school- 
and non-school based immunization program. Vaccine. 2014 Jan 9;32(3):320–6.  
145. Musto R, Siever JE, Johnston JC, Seidel J, Rose MS, McNeil DA. Social equity in Human 
Papillomavirus vaccination: a natural experiment in Calgary Canada. BMC Public Health. 
2013;13:640.  
146. Lefevere E, Theeten H, Hens N, De Smet F, Top G, Van Damme P. From non school-based, co-
payment to school-based, free Human Papillomavirus vaccination in Flanders (Belgium): A 
retrospective cohort study describing vaccination coverage, age-specific coverage and socio-
economic inequalities. Vaccine. 2015 Sep 22;33(39):5188–95.  
147. Rehn M, Uhnoo I, Kühlmann-Berenzon S, Wallensten A, Sparén P, Netterlid E. Highest Vaccine 
Uptake after School-Based Delivery - A County-Level Evaluation of the Implementation 
Strategies for HPV Catch-Up Vaccination in Sweden. PLOS ONE. 2016 Mar 14;11(3):e0149857.  
148. Swedish Cancer Registry [Internet]. [cited 2017 Oct 7]. Available from: 
http://www.socialstyrelsen.se/register/halsodataregister/cancerregistret/inenglish 
149. Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer 
Register – a sample survey for year 1998. Acta Oncol. 2009 Jan 1;48(1):27–33.  




151. Ludvigsson JF, Almqvist C, Bonamy A-KE, Ljung R, Michaëlsson K, Neovius M, et al. 
Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 
2016 Feb 1;31(2):125–36.  
152. Brooke HL, Talbäck M, Hörnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish 
cause of death register. Eur J Epidemiol. 2017 Oct 5;1–9.  
153. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim J-L, Reuterwall C, et al. External 
review and validation of the Swedish national inpatient register. BMC Public Health. 2011 Jun 
9;11(1):450.  
154. Longitudinal integration database for health insurance and labour market studies (LISA by 
Swedish acronym) [Internet]. Statistiska Centralbyrån. [cited 2017 May 18]. Available from: 
http://www.scb.se/lisa-en 
155. Ludvigsson JF, Håberg SE, Knudsen GP, Lafolie P, Zoega H, Sarkkola C, et al. Ethical aspects 
of registry-based research in the Nordic countries [Internet]. Clinical Epidemiology. 2015 [cited 
2017 Nov 2]. Available from: https://www.dovepress.com/ethical-aspects-of-registry-based-
research-in-the-nordic-countries-peer-reviewed-article-CLEP 
156. World Health Organization (1956). Statistical Code for Human tumours 
(WHO/HS/CANC./24.1). Geneva: World Health Organization;  
157. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United 
States, 1988-1990. Obstet Gynecol. 1994 Apr;83(4):549–55.  
158. Vessey MP, Villard-Mackintosh L, McPherson K, Coulter A, Yeates D. The epidemiology of 
hysterectomy: findings in a large cohort study. Br J Obstet Gynaecol. 1992 May;99(5):402–7.  
159. Lundholm C, Forsgren C, Johansson AL v., Cnattingius S, Altman D. Hysterectomy on benign 
indications in Sweden 1987–2003: A nationwide trend analysis. Acta Obstet Gynecol Scand. 
2009 Jan 1;88(1):52–8.  
160. Swedish National Cervial Screening Registry: Annual Report 2013 [Internet]. [cited 2014 Aug 
6]. Available from: 
http://www.cancercentrum.se/Global/RCC%20Samverkan/Dokument/Screening/NKCx_%C3%A
5rsrapport_2013.pdf 
161. Pimenta JM, Galindo C, Jenkins D, Taylor SM. Estimate of the global burden of cervical 
adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC 
Cancer. 2013 Nov 21;13:553.  
162. Kjaer SK, Brinton LA. Adenocarcinomas of the Uterine Cervix: The Epidemiology of an 
Increasing Problem. Epidemiol Rev. 1993 Jan 1;15(2):486–91.  
163. Widrich T, Kennedy AW, Myers TM, Hart WR, Wirth S. Adenocarcinomain Situof the Uterine 
Cervix: Management and Outcome. Gynecol Oncol. 1996 Jun;61(3):304–8.  
164. Kennedy AW, Biscotti CV. Further Study of the Management of Cervical Adenocarcinoma in 
Situ. Gynecol Oncol. 2002 Sep;86(3):361–4.  
165. Costales AB, Milbourne AM, Rhodes HE, Munsell MF, Wallbillich JJ, Brown J, et al. Risk of 
residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the 
cervix. Gynecol Oncol. 2013 Jun;129(3):513–6.  
166. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risk of 
CIN3+ and cervical cancer for women with HPV-positive and HPV-negative high-grade Pap 
results. J Low Genit Tract Dis. 2013 Apr;17(5 0 1):S50–5.  
167. Wijngaarden WJV, Duncan ID. Rationale for stopping cervical screening in women over 50. 
BMJ. 1993 Apr 10;306(6883):967–71.  
  65 
168. Armaroli P, Gallo F, Bellomi A, Ciatto S, Consonni D, Davi D, et al. Do women ⩾50 years of 
age need as much screening as women <50 years after they have had negative screening results? 
Br J Cancer. 2008 Jul 1;99(2):239–44.  
169. Kamineni A, Weinmann S, Shy KK, Glass AG, Weiss NS. Efficacy of screening in preventing 
cervical cancer among older women. Cancer Causes Control. 2013 Jun 7;24(9):1653–60.  
170. Reijneveld SA. Reported health, lifestyles, and use of health care of first generation immigrants 
in The Netherlands: do socioeconomic factors explain their adverse position? J Epidemiol 
Community Health. 1998 May 1;52(5):298–304.  
171. Shelton RC, Jandorf L, Thelemaque L, King S, Erwin DO. Sociocultural determinants of breast 
and cervical cancer screening adherence: an examination of variation among immigrant Latinas 
by country of origin. J Health Care Poor Underserved. 2012 Nov;23(4):1768–92.  
172. Azerkan F, Sparén P, Sandin S, Tillgren P, Faxelid E, Zendehdel K. Cervical screening 
participation and risk among Swedish-born and immigrant women in Sweden. Int J Cancer. 2012 
Feb 15;130(4):937–47.  
173. Broberg G, Wang J, Östberg A-L, Adolfsson A, Nemes S, Sparen P, et al. Socio-economic and 
demographic determinants affecting participation in the Swedish cervical screening program: a 
population-based case-control study. PLOS ONE. in press.  
174. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009) [Internet]. 
CEBM. 2009 [cited 2017 Oct 23]. Available from: http://www.cebm.net/oxford-centre-evidence-
based-medicine-levels-evidence-march-2009/ 
175. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and 
human papillomavirus in cervical cancer: the IARC multicentric case-control study. The Lancet. 
2002 Mar 30;359(9312):1093–101.  
176. Brinton LA, Reeves WC, Brenes MM, Herrero R, DE BRIlTON, Gaitan E, et al. PARITY AS A 
RISK FACTOR FOR CERVICAL CANCER. Am J Epidemiol. 1989 Sep 1;130(3):486–96.  
177. Wardle J, Steptoe A. Socioeconomic differences in attitudes and beliefs about healthy lifestyles. J 
Epidemiol Community Health. 2003 Jun 1;57(6):440–3.  
178. Inglis V, Ball K, Crawford D. Why do women of low socioeconomic status have poorer dietary 
behaviours than women of higher socioeconomic status? A qualitative exploration. Appetite. 
2005 Dec 1;45(3):334–43.  
179. Albert A. Estimated cervical cancer disease state incidence and transition rates. J Natl Cancer 
Inst. 1981 Sep;67(3):571–6.  
180. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of 
cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: 
a retrospective cohort study. Lancet Oncol. 2008 May;9(5):425–34.  
181. Eaker S, Adami H-O, Granath F, Wilander E, Sparén P. A Large Population-Based Randomized 
Controlled Trial to Increase Attendance at Screening for Cervical Cancer. Cancer Epidemiol Prev 
Biomark. 2004 Mar 1;13(3):346–54.  
182. Virtanen A, Anttila A, Luostarinen T, Malila N, Nieminen P. Improving cervical cancer 
screening attendance in Finland. Int J Cancer. 2015 Mar 15;136(6):E677–84.  
183. Taylor RJ, Mamoon HA, Morrell SL, Wain GV. Cervical screening by socio-economic status in 
Australia. Aust N Z J Public Health. 2001 Jun 1;25(3):256–60.  
184. Akers AY, Newmann SJ, Smith JS. Factors Underlying Disparities in Cervical Cancer Incidence, 
Screening, and Treatment in the United States. Curr Probl Cancer. 2007 May;31(3):157–81.  
 66 
185. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-
based screening for prevention of invasive cervical cancer: follow-up of four European 
randomised controlled trials. The Lancet. 2014 Feb 14;383(9916):524–32.  
186. Strander B, Hällgren J, Sparén P. Effect of ageing on cervical or vaginal cancer in Swedish 
women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort 
study of long term incidence and mortality. BMJ. 2014 Jan 14;348:f7361.  
187. Herweijer E, Feldman AL, Ploner A, Arnheim-Dahlström L, Uhnoo I, Netterlid E, et al. The 
Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-
Based Cohort Study. PLOS ONE. 2015 Jul 28;10(7):e0134185.  
 
